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I. Introduction		
In recent years, cannabis products that have not received approval 
from the U.S. Food and Drug Administration (FDA) have become 
increasingly popular.  Non-FDA-approved products containing delta-9-
tetrahydrocannabinol (THC) and cannabidiol (CBD), such as tinctures, 
gummies and other edibles, lotions, pills, and vaping oils and inhalation 
products, are sold everywhere from high-end beauty stores to local gas 
stations.  The growing availability of these products is largely due to 
states’ concerted efforts to enact laws legalizing non-FDA-approved 
cannabis products.1  These laws create unique challenges for employers, 
including workplace safety issues and personnel decisions, including 
hiring, firing, and disciplinary actions.  Employers must also wrestle 
with the fact that their employees may use cannabis for medical reasons, 
even though the cannabis products that their employees use have not 
undergone the FDA’s rigorous review and approval process, and 
therefore, have unknown safety and efficacy profiles, as well as 
unpredictable composition and quality. 
Despite the recent passage of the Agriculture Improvement Act of 
2018 (“the Farm Bill”), which was intended to carve out hemp-derived 
products from the definition of “marijuana” under the federal Controlled 
Substances Act (CSA),2 most non-FDA-approved cannabis products 
remain illegal under the CSA and the Food, Drug, and Cosmetics Act 
(FDCA).3  Marijuana is still a Schedule I substance under the CSA, 
meaning that it has no currently accepted medical use and has a high 
potential for abuse.4  Additionally, non-FDA-approved cannabis 
products, including CBD products, are often marketed for therapeutic 
purposes in violation of the FDCA.5  The FDCA only permits 
 
	 1	 See	State	Medical	Marijuana	Laws, NAT’L CONFERENCE OF STATE LEGISLATURES, (Oct. 12, 
2020), https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.  
 2 The Agriculture Improvement Act of 2018 defines “hemp” as “the plant Cannabis 
sativa L. and any part of that plant, including the seeds thereof and all derivatives, 
extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or 
not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on 
a dry weight basis.”  7 U.S.C. § 1639o(1). 
 3 21 U.S.C. § 812 Schedule 1 (c)(17) (setting forth Schedule 1 controlled 
substances); 21 C.F.R. §§ 1308.11(d)(23), (58); 21 U.S.C. § 331(a) (stating that an 
unapproved new drug cannot be sold in interstate commerce under the FDCA).  Illegality 
under the FDCA stems from two different theories. Non-hemp products are illegal per	se 
in foods, dietary supplements, and drugs.  All cannabis, including hemp products, that 
make therapeutic claims are illegal unless they are FDA-approved drugs.  
 4 21 U.S.C. § 812(b)(1). 
 5 21 U.S.C. §§ 321(g)(1), 331 (a), 352(a); see,	 e.g., FDA	Warns	15	Companies	 for	
Illegal	Selling	Various	Products	Containing	Cannabidiol	as	Agency	Details	Safety	Concerns, 
WORTHY (DO NOT DELETE) 4/27/2021  11:16 PM 
2021]	 DAZED	AND	CONFUSED 379 
manufacturers of FDA-approved drugs to make therapeutic claims 
about their products.6  Currently, the FDA has only approved four 
prescription drugs containing cannabis – one cannabis-derived and 
three cannabis-related drugs.7  These drugs include one product 
containing cannabis plant-derived CBD as its active ingredient, two 
products that include the active ingredient dronabinol (i.e., a synthetic 
THC), and one product containing the active ingredient nabilone (i.e., a 
synthetic product with a chemical structure similar to THC).8  The FDA-
approved CBD product is specifically indicated for the treatment of 
seizures associated with three rare and severe forms of epilepsy, 
Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis 
Complex; dronabinol is indicated for the treatment of anorexia 
associated with weight loss in patients with AIDS; and both dronabinol 
and nabilone are indicated for nausea and vomiting associated with 
cancer chemotherapy.9  Yet, manufacturers of non-FDA-approved 
cannabis products have made unsubstantiated claims that their 
products can be used to prevent, diagnose, mitigate, treat, or cure 
several medical conditions, including: Alzheimer’s Disease, autism, 
cancer, diabetes, heart disease, kidney disease, liver disease, opioid use 
disorder, Parkinson’s Disease, and most recently, COVID-19.10 
Additionally, manufacturers of non-FDA-approved cannabis 
products have marketed their products as dietary supplements or 
 
FDA (Nov. 25, 2019),	 https://www.fda.gov/news-events/press-announcements/fda-
warns-15-companies-illegally-selling-various-products-containing-cannabidiol-
agency-details [hereinafter FDA	Warns	15	Companies].  
 6 21 U.S.C. §§ 321(g)(1), 331 (a), 352(a). 
	 7	 FDA	Regulation	of	Cannabis	and	Cannabis‐Derived	Products,	Including	Cannabidiol	
(CBD), FDA (Oct. 1, 2020), https://www.fda.gov/news-events/public-health-focus/fda-
regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-
cbd#farmbill [hereinafter FDA	Regulation	of	CBD]. 
	 8	 Epidiolex Label, Greenwich Biosciences, 
https://www.epidiolex.com/sites/default/files/pdfs/1120/EPX-03645-
1120_EPIDIOLEX_(cannabidiol)_USPI.pdf#page=9; Marinol	 Label, FDA (Revised Aug. 
2017),	
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf; 
Syndros	 Label, FDA (Revised July 2016), 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205525s000lbl.pdf; 
Cesamet	 NDA, FDA (Revised May 2006)	
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf.   
	 9	 Id.	 
	 10	 See	Warning	Letter:	Homero	Corp	DBA	Natures	CBD	Oil	Distribution, FDA (Apr. 20, 
2020),	 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-
investigations/warning-letters/homero-corp-dba-natures-cbd-oil-distribution-
605222-04202020; Warning	 Letter:	 CBD	 Gaze, FDA (May 26, 2020), 
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-
investigations/warning-letters/cbd-gaze-607299-05262020.	
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food.11  Yet, the FDA has clearly stated that it is illegal to market such 
non-FDA approved cannabis products by adding them to food or 
labeling them as dietary supplements.12  Nonetheless, FDA is “concerned 
at the proliferation of such products.”13 In light of the lack of regulatory 
oversight and enforcement against illegal drug products, employees 
who use such products could be at risk of ingesting high concentrations 
of THC or contaminated and unsafe substances, including undisclosed 
pesticides, heavy metals, and controlled substances, such as K2/spice.14  
Use of these products creates particularly unique challenges for 
employers given that THC can cause impairment.15 
Arguably there are minimal differences between medical and 
recreational cannabis beyond their “intent of use” and cost.  Yet, at least 
six states have introduced legislation to require health plans and 
workers’ compensation programs to cover non-FDA-approved cannabis 
products for medical purposes, despite the lack of safety and efficacy 
requirements.16  Such legislation directly conflicts with federal laws, 
such as the CSA and the FDCA, poses health risks to employees, and 
increases risk of liability for employers.  As such, states should not enact 
these mandates.   
Part II of this Article defines key terminology and provides an 
overview of relevant federal laws, such as the Farm Bill of 2018, the CSA, 
 
	 11	 FDA	Regulation	of	Dietary	Supplement	&	Conventional	Food	Products	Containing	
Cannabis	 and	 Cannabis‐Derived	 Compounds, FDA, 
https://www.fda.gov/media/131878/download (last visited Nov. 3, 2020).  
	 12	 What	You	Need	to	Know	(And	What	We’re	Working	to	Find	Out)	About	Products	




ry%20supplement (last updated Mar. 5, 2020) [hereinafter What	You	Need	to	Know	(And	
What	We’re	Working	 to	 Find	 Out)].  But note that the FDA considers certain foods 
containing hemp and hemp seed-derived food ingredients to be “generally recognized 
as safe” or GRAS.  FDA	Responds	to	Three	GRAS	Notices	for	Hemp	Seed‐Derived	Ingredients	
for	 Use	 in	 Human	 Food, FDA, (Dec. 20, 2018), https://www.fda.gov/food/cfsan-
constituent-updates/fda-responds-three-gras-notices-hemp-seed-derived-ingredients-
use-human-food. 
	 13	 FDA	Regulation	of	CBD,	supra	note	7.	 
 14 Lisa Fletcher, The	Risk	of	Contaminants	and	False	Labeling	in	the	Exploding	CBD	
Industry, WJLA (May 15, 2019),	https://wjla.com/features/7-on-your-side/the-risk-of-
contaminants-and-false-labeling-in-the-exploding-cbd-industry.  
	 15	 See Report	 to	 the	U.S.	House	 Committee	 on	 Appropriations	 and	 the	U.S.	 Senate	
Committee	on	Appropriations,	Sampling	Study	of	the	Current	Cannabidiol	Marketplace	to	
Determine	 the	 Extent	 that	 Products	 Are	 Mislabeled	 or	 Adulterated, FDA (2020), 
https://hempindustrydaily.com/wp-content/uploads/2020/07/CBD-Marketplace-
Sampling_RTC_FY20_Final.pdf. 
	 16	 See	infra	Part III.A. 
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FDCA, and state laws governing the use of cannabis products.  Part III 
analyzes proposed legislation that would mandate coverage of non-
FDA-approved cannabis products  and how that legislation may directly 
conflict with various federal laws, creating the potential for employer 




The federal and some state governments have enacted legislation 
with the intent to legalize non-FDA-approved cannabis products, 
including CBD products.  There are, however, other federal laws that 
directly conflict with these state legalization efforts.  Additionally, 
products currently sold to the public oftentimes do not comply with the 
federal or state laws that intended to legalize such products.  This 
section defines key terminology and summarizes those relevant laws. 
A. TERMINOLOGY  
The terms “cannabis” and “marijuana” are often used 
interchangeably, however, they do not have the same meaning. 17  
“Cannabis” refers to “a plant of the Cannabaceae family and contains 
more than eighty biologically active chemical compounds,” with the 
most commonly known compounds being THC and CBD. 18  Under 
federal law, the term “marijuana” (or “marihuana”) refers to “all parts of 
the plant Cannabis	sativa	L., whether growing or not; the seeds thereof; 
the resin extracted from any part of such plant; and every compound, 
manufacture, salt, derivative, mixture, or preparation of such plant, its 
seeds or resin.” 19  Additionally, according to a recent interim final rule 
from the U.S. Drug Enforcement Administration (“DEA”), “marihuana 
extract” is defined as “an extract containing one or more cannabinoids 
that has been derived from any plant of the genus Cannabis, containing 
greater	than	0.3	percent	delta-9-tetrahydrocannabinol on a dry weight 
basis, other than the separated resin (whether crude or purified) 
obtained from the plant.”20  “Marihuana” does not include “hemp” as that 
term is defined or: 
 
 17 Cannabis	(Marijuana)	and	Cannabinoids:	What	You	Need	To	Know, NIH NAT’L CTR. 
FOR COMPLEMENTARY & INTEGRATIVE HEALTH,	https://www.nccih.nih.gov/health/cannabis-
marijuana-and-cannabinoids-what-you-need-to-know (last updated Nov. 2019). 
 18 FDA	Regulation	of	CBD, supra	note 7. 
 19 21 U.S.C. § 802(16)(A). 
 20 Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639, 
51641–42 (Aug. 21, 2020) (interim final rule) (emphasis added); but	 see, Brief of 
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the mature stalks of such plant, fiber produced from such 
stalks, oil or cake made from the seeds of such plant, any other 
compound, manufacture, salt, derivative, mixture, or 
preparation of such mature stalks (except the resin extracted 
therefrom), fiber, oil, or cake, or the sterilized seed of such 
plant which is incapable of germination.21  
 
“Hemp” is defined as “the plant Cannabis	sativa	L. and any part of 
that plant, including the seeds thereof and all derivatives, extracts, 
cannabinoids, isomers, acids, salts, and salts of isomers, whether 
growing or not, with a delta-9 tetrahydrocannabinol concentration of	
not	more	than	0.3	percent on a dry weight basis.”22  Hemp is an industrial 
plant once cultivated exclusively for its fiber and edible seeds.23  While 
hemp is a variety of the cannabis plant, hemp varieties are lower in THC 
content than marijuana plants, as required by U.S. law.24  
THC is the main psychoactive constituent of marijuana and is 
primarily responsible for the intoxicating and impairing effects that 
marijuana has on a person’s mental state.25  Cannabinoids are “[a]ny of 
the various naturally occurring, biologically active chemical 
constituents of hemp or cannabis, including some that possess 
psychoactive properties,” such as THC.26  CBD is a non-psychogenic 
cannabinoid derived from marijuana or synthesized.27  
In this Article, the term “non-FDA-approved cannabis products” is 
used as a catchall term.  It includes all products that are illegal under the 
CSA (i.e., marijuana, marijuana extract, and THC) and illegal under the 
FDCA (i.e., non-FDA-approved products regardless of whether they are 
derived from hemp or marijuana, or in other words, regardless of 
whether they contain less than 0.3 percent THC).  The term does not 
 
Petitioner at 5, Hemp Indus. Ass’n v. DEA, No. 20-1376 (D.C. Cir. Sept. 18, 2020) 
(challenging the legality of the Interim Final Rule). 
 21 21 U.S.C. § 802(16)(B). 
 22 7 U.S.C. § 1639o(1) (emphasis added). 
 23 Dana Sullivan Kilroy, Speaking	the	Endocannabinoid	System:	A	Glossary	of	Terms	
Used	 to	Describe	Marijuana,	 Cannabidiol,	 the	Endocannabinoid	 System,	 and	Cannabis, 
EVERYDAY HEALTH (Nov. 6, 2019),	 https://www.everydayhealth.com/marijuana/cbd-
oil/glossary/. 
	 24	 Id.  
	 25	 Cannabis	(Marijuana)	and	Cannabinoids:	What	You	Need	To	Know, supra	note 17. 
 26 Kilroy, supra	note 24. 
	 27	 Common	 Terminology	 &	 Glossary, THE COLLABORATIVE FOR CBD SCI. & SAFETY,	
https://a2890a0f-5011-4a6c-a93d-
804dc45494d5.usrfiles.com/ugd/a2890a_b3d21d5fcebb49669a5191ef4dcf0a2a.pdf 
(last visited Nov. 3, 2020). 
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include food products containing hemp that the FDA has deemed legal 
(i.e., certain foods containing hemp and hemp seed-derived food 
ingredients that the FDA consider to be “generally recognized as safe” 
or “GRAS”).28  The term also does not include CBD-containing cosmetics, 
which the FDA does not prohibit outright, unless such products make 
improper therapeutic claims.29 
B. THE CSA  
Enacted in 1970, the CSA provides the DEA with regulatory 
authority over controlled substances, including the authority over the 
manner in which controlled substances are imported, manufactured, 
distributed, possessed, and used.30  Controlled substances are drugs or 
other substances with abuse potential.31  The DEA categorizes a 
controlled substance within five schedules based on their medical 
effectiveness and abuse potential.32  
Schedule I is reserved for substances with (1) the highest potential 
for abuse, (2) no currently accepted medical use in the U.S., and (3) a 
lack of accepted safe use under medical supervision.33  Under the CSA, it 
is a crime to “knowingly or intentionally . . . possess” and to “knowingly 
or intentionally . . . manufacture, distribute, or dispense, or possess with 
the intent to manufacture, distribute, or dispense” a Schedule I 
substance.34  Marijuana is regulated as a Schedule I substance.35  THC 
(except for THC in hemp) is also a Schedule I substance.36  The CSA 
prohibits possession and distribution of non-FDA-approved marijuana 
even for medical use, regardless of whether a state has enacted a law to 
allow such use.37  The CSA, however, does permit marijuana to be used 
in research by properly-licensed researchers.38 
 
	 28	 FDA	Responds	to	Three	GRAS	Notices	for	Hemp	Seed‐Derived	Ingredients	for	Use	in	
Human	Food, supra	note 12. 
	 29	 FDA	Regulation	of	CBD, supra	note 7. 
	 30	 See	21 U.S.C. §§ 801, 811. 
 31 21 U.S.C. §§ 802(6), 811(c). 
	 32	 See	21 U.S.C. §§ 811, 812. 
 33 21 U.S.C. § 812(b)(1). 
 34 21 U.S.C. § 841(a)(1). 
 35 21 U.S.C. § 812(c)(10); 21 C.F.R. §§ 1308.11(d)(23), (58). 
 36 21 U.S.C. § 812 Schedule 1(c)(17). 
	 37	 See	Gonzales v. Raich, 545 U.S. 1, 29 (2005). 
 38 21 U.S.C. § 822(b); Controls to Enhance the Cultivation of Marihuana for Research 
in the United States, 85 Fed. Reg. 82333, 82338 (Dec. 18, 2020) (Final Rule).  
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C. THE FARM BILL 
In December 2018, Congress passed the Farm Bill, which among 
other things, made changes related to the production and marketing of 
hemp.39  As noted above, the Farm Bill defined “hemp” as “the plant	
Cannabis	sativa	L. and any part of that plant, including the seeds thereof 
and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts 
of isomers, whether growing or not, with a delta-9 
tetrahydrocannabinol concentration of not more than 0.3 percent on a 
dry weight basis.”40  It also amended the CSA by removing hemp from 
the CSA’s definition of marijuana and the Schedule I listing of THC. 41  As 
a result, hemp-derived products (including hemp-derived CBD 
products) containing less than 0.3 percent THC that were produced with 
less than 0.3 percent THC extract are no longer considered controlled 
substances under federal law.42  Conversely, any marijuana products 
with levels of THC above the 0.3 percent cut-off are not considered to be 
“hemp products” and are, therefore, still regulated as Schedule I 
controlled substances under the CSA.43   
On August 26, 2019, the DEA announced that it would no longer 
require registration to grow, research, or manufacture hemp because 
hemp was “not a controlled substance.”44  On August 21, 2020, the DEA 
issued an interim final rule (“IFR”), which was intended to codify 
regulations required by the Farm Bill.45  The DEA stated that the IFR 
 
	 39	 FDA	Regulation	of	CBD, supra	note 7. 
	 40	 FDA	Regulation	of	CBD, supra	note 7 (emphasis added); cf. Agricultural Act of 2014, 
Pub. L. No. 113-79, § 7606(b)(2), 128 Stat. 912-13 (2014).  Congress enacted the 
Agricultural Act of 2014 (2014 Farm Bill), which initially defined “industrial hemp” as 
“the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a 
delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry 
weight basis.”  The 2014 Farm Bill allowed institutes of higher education and state 
departments of agriculture to grow and cultivate industrial hemp for research in limited 
circumstances.  The 2014 Farm Bill did not, however, remove hemp from the schedules 
of controlled substances under the CSA.  
 41 CONGRESSIONAL RESEARCH SERVICE, R44742,	 Defining	 Hemp:	 A	 Fact	 Sheet,  
https://fas.org/sgp/crs/misc/R44742.pdf (updated Mar. 22, 2019). 
	 42	 FDA	Regulation	of	CBD, supra	note 7. 
	 43	 FDA	Regulation	of	CBD, supra	note 7. 
	 44	 DEA	Announces	 Steps	Necessary	 to	 Improve	Access	 to	Marijuana	Research, DEA 
(Aug. 26, 2019),	 https://www.dea.gov/press-releases/2019/08/26/dea-announces-
steps-necessary-improve-access-marijuana-research.  
 45 The regulations state that the definition of THC does not include “any material, 
compound, mixture, or preparation that falls within the definition of hemp,” and it stated 
that the definition of “marihuana extract” is limited to extracts “containing greater than 
0.3 percent delta-9-tetrahydrocannabinol on a dry weight basis.”  The IFR also removed 
FDA-approved products containing CBD from schedule V, among other changes.  
Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639–40 
(Aug. 21, 2020) (interim final rule). 
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“merely conforms DEA’s regulations to the statutory amendments to the 
CSA that have already taken effect.”46  But, the IFR defined “marihuana 
extract” as extracts “containing greater than 0.3 percent delta-9-
tetrahydrocannabinol on a dry weight basis.”47  This means that if a 
hemp product contains intermediate extracts of 0.3 percent THC at 
some point during the manufacturing process, then it is still considered 
a Schedule I controlled substance, even if the finished product has less 
than 0.3 percent THC.48  In response, Hemp Industries Association and 
RE Botanicals Association filed suit against the DEA in the U.S. Court of 
Appeals for the D.C. Circuit to challenge the rule.49  The case is still 
pending. The DEA, for now, will not regulate hemp-derived products 
containing less than 0.3 percent THC of a dry weight basis and that were 
produced using intermediate extracts containing less than 0.3 percent 
THC.  The DEA will, however, continue to regulate marijuana and 
marijuana extract products containing more than 0.3 percent THC on a 
dry weight basis as illicit Schedule I substances, at least while the IFR 
remains in place.  
At the same time, the Farm Bill “explicitly preserved FDA’s 
authority to regulate products containing cannabis or cannabis-derived 
compounds under the [FDCA] and section 351 of the Public Health 
Service Act (PHS Act).”50  According to the FDA, all cannabis and 
cannabis-derived products are “subject to the same authorities and 
requirements as any other FDA-regulated products[.]”51 
D. THE FOOD, DRUG, AND COSMETICS ACT 
Originally enacted in 1938, the FDCA provides the FDA with the 
authority to regulate food, drug, and cosmetic products, by, among other 
things, creating regulatory pathways for products and enforcing 
consumer protection provisions.52  Under the act, the FDA defines a 
prescription drug as “a substance intended for use in the diagnosis, cure, 
 
	 46	 Id. 
	 47	 Id.  
	 48	 Id.	at 51640–41. 
 49 Brief of Petitioner at 5, Hemp Indus. Ass’n v. DEA, No. 20-1376 (D.C. Cir. Sept. 18, 
2020).  Petitioners argue that 1) the DEA promulgated the IRF without complying with 
the proper procedure required by law; 2) the rule exceeds statutory jurisdiction, 
authority, or limitations; and 3) the IFR is arbitrary, capricious, an abuse of discretion, 
or otherwise not in accordance with law in violation of the Administrative Procedures 
Act.  Id.  
	 50	 FDA	Regulation	of	CBD, supra	note 7. 
	 51	 FDA	Regulation	of	CBD, supra	note 7. 
	 52	 How	 Did	 the	 Federal	 Food,	 Drug,	 and	 Cosmetic	 Act	 Come	 About?, FDA,	
https://www.fda.gov/about-fda/fda-basics/how-did-federal-food-drug-and-cosmetic-
act-come-about (last updated Mar. 28, 2018). 
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mitigation, treatment, or prevention of disease” that is prescribed by a 
health care practitioner and regulated by the FDA.53  Prior to marketing, 
a prescription drug must meet the FDA’s standards for safety and 
efficacy.54  Drugs must also uniformly meet standards regarding quality, 
purity, and dosage.55  The FDA applies rigorous standards and requires 
substantial scientific evidence to prove a product meets the safety and 
efficacy requirements for its intended use before it is approved as a 
drug.56  A drug without the FDA’s prior approval is deemed a “new drug” 
under the FDCA, and it cannot be introduced, distributed, or sold in 
interstate commerce.57  
In contrast, the FDCA defines a dietary supplement as a product 
that is intended to supplement a diet, contains one or more dietary 
ingredient (e.g., vitamins, minerals, herbs), and is intended to be taken 
orally.58  The FDA does not review dietary supplements for safety or 
efficacy before they are marketed in the U.S. unless they contain new 
dietary ingredients.59  Additionally, while the FDA has established good 
manufacturing practices (GMPs) that manufacturers must comply with 
to help ensure the identity, purity, strength, and composition of their 
products, the FDA does not have a regulatory pathway ensuring the 
safety and efficacy of dietary supplements in the U.S. through a pre-
approval process as is applicable to drugs.60   
Moreover, dietary supplements are intended to support a 
consumer’s diet rather than treat a patient’s medical condition.61  If a 
 
 53 21 U.S.C.S. § 321(g)(1)(B); Prescription	Drugs	and	Over‐the‐Counter	(OTC)	Drugs:	
Questions	 and	 Answers, FDA,	 https://www.fda.gov/drugs/questions-
answers/prescription-drugs-and-over-counter-otc-drugs-questions-and-answers (last 
updated Nov. 13, 2017). 
 54 21 U.S.C.S. § 321(p)(1). 
 55 21 C.F.R. § 211.22(c). 
 56 21	 U.S.C. § 355(d) (defining “substantial evidence” as that which generally 
consists of data from “adequate and well-controlled” clinical trials); 21 C.F.R. § 314.126; 
see	also	21	U.S.C. § 393(b)(2)(B); FDA v. Brown & Williamson Tobacco Corp.,	529 U.S. 
120, 133 (2000).   
 57 21 U.S.C. § 331. 
	 58	 Questions	 and	 Answers	 on	 Dietary	 Supplements, FDA,	
https://www.fda.gov/food/information-consumers-using-dietary-
supplements/questions-and-answers-dietary-supplements (last updated July 22, 
2019). 
	 59	 What	You	Need	to	Know	(And	What	We’re	Working	to	Find	Out), supra	note 12; 21 
U.S.C. § 350b(d).  The FDCA defines a “new dietary ingredient” as “a dietary ingredient 
that was not marketed in the United States before October 15, 1994 and does not include 
any dietary ingredient which was marketed in the United States before October 15, 
1994.” 21 U.S.C. § 350b(d). 	
	 60	 What	You	Need	 to	Know	(And	What	We’re	Working	 to	Find	Out), supra	note 12; 
Questions	and	Answers	on	Dietary	Supplements, supra note 58. 
 61 21 U.S.C. § 321(ff). 
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dietary supplement manufacturer makes therapeutic claims about its 
product, then the product would be an illegal new and misbranded drug, 
in violation of the FDCA.62  Such products would be considered “drugs” 
rather than “supplements” under the FDCA because they are intended 
for use in the diagnosis, cure, mitigation, treatment, or prevention of 
disease, or intended to affect the structure or any function of the body.63  
Yet, given that supplements are not FDA-approved, supplements with 
therapeutic claims are not generally recognized as safe and effective for 
the claimed uses.64  Such supplements, therefore, are new drugs under 
the FDCA which cannot be introduced into interstate commerce until 
they receive FDA approval.65  
These provisions notwithstanding, marketers frequently claim that 
their cannabis and cannabis-derived products treat serious medical 
conditions even though they have not been approved by the FDA and 
there is no substantial evidence of effectiveness or safety.66  Yet, the FDA 
has not approved marijuana as a “drug” for therapeutic use under the 
FDCA.  As mentioned, the agency has only approved one cannabis-
derived and three cannabis-related products.  The FDA has also stated 
that irrespective of claims, CBD and THC are only permissible in FDA-
approved drugs and are not permissible ingredients in foods or dietary 
supplements.67  
In other words, the FDA authorized the study of, and approved the 
use of, a prescription drug containing CBD or THC prior to the marketing 
of CBD and THC as a dietary supplement or an ingredient in food.68 
 
 62 21 U.S.C. § 352(f)(1). 
 63 21 U.S.C. § 321(g). 
 64 21 U.S.C. § 321(ff)(3)(B). 
 65 21 U.S.C. § 331. 
	 66	 FDA	Regulation	of	CBD, supra	note 7. 
	 67	 Statement	from	FDA	Commissioner	Scott	Gottlieb	M.D.,	on	Signing	of	the	Agriculture	
Improvement	 Act	 and	 the	 Agency’s	 Regulation	 of	 Products	 Containing	 Cannabis	 and	
Cannabis‐Derived	 Compounds, FDA (Dec. 20, 2018),	 https://www.fda.gov/news-
events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-
agriculture-improvement-act-and-agencys (“It is unlawful under the [FDCA] to 
introduce food containing added CBD or THC into interstate commerce, or to market 
CBD or THC products as, or in, dietary supplements, regardless of whether the 
substances are hemp-derived.  This is because both CBD and THC are active ingredients 
in FDA-approved drugs and were the subject of substantial clinical investigations before 
they were marketed as foods or dietary supplements.  Under the [FDCA], it’s illegal to 
introduce drug ingredients like these into the food supply, or to market them as dietary 
supplements.”) [hereinafter Statement	from	FDA	Commissioner	Gottlieb]. 
 68 As of November 11, 2020, the FDA has approved one CBD drug product 
(Epidiolex).  Orange	 Book:	 Approved	 Drug	 Products	 with	 Therapeutic	 Equivalence	
Evaluations, FDA, https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm (last 
visited March 13, 2021) (search “cannabidiol”).  
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Therefore, no food or dietary supplement may contain CBD or THC; they 
are excluded from the FDCA’s definition of dietary supplement,69 and 
they are not permissible in foods because they are not GRAS or an 
approved additive.70  CBD and THC cannot, therefore, be introduced into 
interstate commerce.71 
The FDA has stated that it has the authority to issue a regulation 
allowing the use of a pharmaceutical ingredient in a food or dietary 
supplement, and the agency is currently in the process of evaluating 
what such a regulatory pathway might look like.72  Until it creates one, 
however, the FDA will continue to deem the marketing of such products 
to be illegal.73   
E. STATE LAW 
While marijuana remains an illegal Schedule I substance under 
federal law, as of the end of 2019, forty-eight states have laws that 
decriminalize or allow the use of non-FDA-approved cannabis products 
under some circumstances.74  States have also enacted their own laws 
governing the manufacture and sale of non-FDA-approved cannabis 
products.  These laws vary significantly from state to state.  For example, 
eleven states and Washington, DC have legalized adult use of cannabis 
products, and fifteen states have decriminalized it.75  “Legalization” 
refers to removing legal prohibitions against the use of cannabis so that 
it is available to the general adult population for purchase and use at 
will, similar to the regulation of tobacco and alcohol products.76  In these 
states, the laws still contain certain limitations, however, such as 
possession limits.77  “Decriminalization” means that cannabis would 
remain illegal, but the individual possessing less than a certain amount 
of cannabis would not be prosecuted.78  The individual may receive no 
 
 69 21 U.S.C. § 321(ff). 
 70 21 U.S.C. § 331 (ll)(3)(C). 
 71 21 U.S.C. § 331. 
	 72	 Statement	from	FDA	Commissioner	Gottlieb, supra note 67. 
	 73	 Statement	from	FDA	Commissioner	Gottlieb, supra note 67. 
 74 Taylor Miller Thomas & Beatrice Jin, The	Dis‐United	States	of	Cannabis, POLITICO 
(Oct. 1, 2019),	https://www.politico.com/interactives/2019/where-is-cannabis-legal-
illegal-by-state/.  
	 75	 Id. 
 76 Dragan M. Svrakic, et. al, Legalization,	 Decriminalization	 &	 Medicinal	 Use	 of	
Cannabis:	A	Scientific	and	Public	Health	Perspective, 109:2 MO. MED. 90 (Mar./Apr. 2012).   
	 77	 See,	e.g., AK. CODE ANN. § 17.38.020; CAL. HEALTH & SAFETY CODE § 11357; COLO. CONST. 
ART. XVIII § 16(3). 
 78 Svrakic, supra	note 76.   
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penalty at all, civil fines, or may be required to obtain drug education or 
treatment.79   
Some states permit the use of non-FDA-approved cannabis 
products for “medical” purposes.  For example, the Maine Medical Use 
of Marijuana Act authorizes qualifying patients to obtain or receive 
cannabis for a medical use.80  Under this law, a qualified patient is 
defined as a “person who has been a resident of the State for at least 30 
days and who possesses a valid written certification regarding medical 
use of marijuana[.]”81  A medical provider provides the written 
certificate for medical use of cannabis, establishing the provider’s 
professional opinion that the patient is likely to receive therapeutic or 
palliative benefit from cannabis.82  
Other states permit limited use of such cannabis products if they 
have low levels of THC or if they contain CBD.83  For example, Iowa’s 
Medical Cannabidiol Act of 2014 allows consumers to possess or use 
FDA-approved CBD products or CBD products containing no more than 
three percent THC and “that is delivered in a form recommended by the 
medical cannabidiol board, approved by the board of medicine, and 
adopted by the [Department of Public Health]” provided that they 
receive certification from a health care provider of medical necessity of 
such products.84  In other states, such as Idaho, all forms and uses of 
cannabis, except for any drugs approved by the FDA, are illegal.85 
 
III. Analysis		
In some states, courts have interpreted state medical marijuana 
laws as requiring employers to reimburse employees for non-FDA-
approved cannabis products as a workers’ compensation benefit,86 and 
other states may soon pass legislation requiring health plans to provide 
 
 79 Svrakic, supra	note 76.   
 80 22 ME. REV. STAT. TIT. 22 § 2423-A (2020). 
 81 22 ME. REV. STAT. TIT. 22 § 2422(9) (2020). 
 82 22 ME. REV. STAT. TIT. 22 § 2423-B (2020). 
	 83	 State	Medical	Marijuana	Laws, supra	note 1.  
 84 IOWA CODE ANN. §§ 124E.2(6) (2020).  “In a prosecution for the unlawful possession 
of marijuana . . . for the possession of medical cannabidiol, . . . it is an affirmative and 
complete defense to the prosecution that the patient has been diagnosed with a 
debilitating medical condition, used or possessed medical cannabidiol pursuant to a 
certification by a health care practitioner . . ., and, for a patient eighteen years of age or 
older, is in possession of a valid medical cannabidiol registration card[.]”  Id.	 at § 
124E.12(4)(a). 
 85 Thomas & Jin, supra	note 74. 
	 86	 See	Hager v. M&K Const., 225 A.3d 137, 140-41 (N.J. Super. Ct. App. Div. 2020).	
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coverage for medical use of non-FDA-approved cannabis products.  But, 
state laws mandating coverage of non-FDA-approved cannabis products 
are in direct conflict with and preempted by certain federal laws.  
Additionally, such laws open employers up for both criminal and tort 
liability.  
A. PROPOSED LEGISLATION  
In recent years, lawmakers in several states have introduced 
legislation to mandate that insurance cover non-FDA-approved 
cannabis products as a health benefit.87  These laws would require 
health plans to provide payment for such products if used by insured 
individuals or employers to reimburse for those products as a workers’ 
compensation benefit through their workers’ compensation insurance 
carrier.88  In January 2020, the New Jersey Assembly introduced A1708, 
which requires workers’ compensation and health insurance coverage 
for medical use of marijuana.89  In January 2020, Hawaii introduced SB 
2586, which requires state-regulated health plans, health maintenance 
organizations, and workers’ compensation programs to reimburse 
qualifying patients up to a certain monthly and annual dollar amount for 
“medical cannabis or manufactured cannabis products.”90  A “qualifying 
 
 87 In addition to the bills described in this section, Maine introduced LD942 and 
Wisconsin introduced SB377 in 2019, both of which would have required certain health 
plans to cover marijuana for medical use.  But, both bills died.  See,	e.g., H.P., 697, 129th 
Leg., 1st Sess. (Me. 2019); WI SB 377, 2019-20 Reg. Sess. (Wis.2019).   
	 88	 See	A. 1708, 219th Leg. (N.J. 2020); S.B. 2054, 2019-20 Reg. Sess. (N.Y. 2020); H. 
3875, 191 Gen. Ct. Leg. (Ma. 2019); H.P., 697, 129th Leg., 1st Sess. (Me. 2019); WI S.B. 
377, 2019-20 Reg. Session (Wis. 2019).   
 89 A. 1708, 219th Leg. (N.J. 2020).  This bill amends Section 16 of P.L. 2009, which 
adopts the definition of marijuana from the New Jersey Controlled Dangerous 
Substances Act.  “Marijuana” is defined as “all parts of the plant genus Cannabis, whether 
growing or not; the seeds thereof; and every compound, manufacture, salt, derivative, 
mixture, or preparation of the plant or its seeds, except those containing resin extracted 
from the plant; but shall not include the mature stalks of the plant, fiber produced from 
the stalks, oil or cake made from the seeds of the plant, any other compound, 
manufacture, salt, derivative, mixture, or preparation of such mature stalks, fiber, oil, or 
cake, or the sterilized seed of the plant which is incapable of germination.”  The 
definition excludes “industrial hemp cultivated pursuant to the New Jersey Industrial 
Hemp Pilot Program.”  Id.; N.J. STAT. ANN. §§ 24:21-2.  
 90 S.B. 2586 , 30th Leg. S.D. 1 (Haw. 2020).  Pursuant to this bill, “medical cannabis” 
has the same meaning as “marijuana” and “marijuana concentrate.”  Id.; HAW. REV. STAT. 
329-121.  “Marijuana” is defined as “all parts of the plant (genus) Cannabis whether 
growing or not; the seeds thereof, the resin extracted from any part of the plant; and 
every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its 
seeds, or resin.  It does not include the mature stalks of the plant, fiber produced from 
the stalks, oil, or cake made from the seeds of the plant, any other compound, 
manufacture, salt, derivative, mixture, or preparation of the mature stalks (except the 
resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is 
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patient” is defined as “a person who has been diagnosed by a physician 
or advanced practice registered nurse as having a debilitating medical 
condition.”91  In January 2019, New York introduced SB 2054, which  
requires that certain state-regulated health plans (e.g., exchange plans, 
Medicaid, and the Children’s Health Insurance Program (CHIP) and 
workers’ compensation) cover marijuana.92  Massachusetts also 
introduced a bill that would require state employee health plans, 
Medicaid managed care organizations, and other state-regulated plans 
to cover “medical use marijuana.”93  All of these bills would mandate 
coverage of non-FDA-approved cannabis products.  
B. HEALTH COVERAGE & BENEFITS  
1. Small	Business	Group	Health	Plans		
Under the Patient Protection and Affordable Care Act (ACA), states 
have regulatory authority over some employer health plans, such as 
group plans offered to employers through the Small Business Health 
Options Program (SHOP).94  
SHOP plans are likely prohibited from covering non-FDA-approved 
cannabis products.  The ACA contains requirements for exchange plans’ 
formulary drug lists (i.e., the list of drugs that a particular health plan 
has decided to cover).95  For example, the ACA requires pharmacy and 
therapeutic committees to base their decisions to include a medication 
 
incapable of germination.”	 	 Id. at § 329-1.  “Marijuana concentrate” means hashish, 
tetrahydrocannabinol, or any alkaloid, salt, derivative, preparation, compound, or 
mixture, whether natural or synthesized, of tetrahydrocannabinol.  HAW. REV. STAT. § 
712-1240 (2020). 
 91 HAW. REV. STAT. § 329-121 (2020). 
 92 S.B. 2054, 2019-20 Reg. Sess. (N.Y. 2020).  New York Public Health Law defines 
“marijuana” as “all parts of the plant of the genus Cannabis, whether growing or not; the 
seeds thereof; the resin extracted from any part of the plant; and every compound, 
manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin.  It 
does not include the mature stalks of the plant, fiber produced from the stalks, oil or 
cake made from the seeds of the plant, any other compound, manufacture, salt, 
derivative, mixture, or preparation of the mature stalks (except the resin extracted 
therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is incapable of 
germination,” and also includes tetrahydrocannabinols or a chemical derivative of 
tetrahydrocannabinol.  N.Y. PUB. HEALTH LAW §§ 3302, 3397-b. 
 93 H. 3875, 191 Gen. Ct. Leg. (Ma. 2019).  “Medical use marijuana” is defined as 
marijuana that is cultivated, processed, transferred, tested, or sold in compliance with 
Massachusetts’s Act to Ensure Safe Access to Marijuana.  935 CMR. § 501.002.  
 94 42 U.S.C. § 300gg-22(a)(1); 45 C.F.R. § 150.101(b)(2); Blueprint	 for	Approval	of	
State‐Based	Health	 Insurance	Exchanges: Coverage	Years	Beginning	On	or	After	2019, 
CMS,https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-
FAQs/Downloads/CMS-Blueprint-Application.pdf (last visited Mar. 24, 2021). 
 95 45 C.F.R. § 156.122. 
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on an exchange plan’s formulary on the “strength of scientific evidence 
and standards of practice,” and “the therapeutic advantages of drug in 
terms of safety and efficacy.” 96 Non-FDA-approved cannabis products 
are Schedule I substances, meaning they lack scientific evidence 
establishing their therapeutic value.97  Additionally, given that such 
substances have not received FDA approval, their safety and efficacy has 
not been demonstrated and cannot be assured.  Thus, an exchange plan, 
including small business plans offered through the SHOP, would likely 
violate the ACA if such substances were included on the plan’s 
formulary.  Moreover, the ACA contains preemption language, which 
notes that states are allowed to adopt and enforce laws that provide 
greater consumer protections, but not weaker protections.98  A state law 
requiring exchange plans to cover non-FDA-approved cannabis 
products would, therefore, likely be preempted by the ACA because it 
would weaken consumer protections in the federal law aimed at 
ensuring consumers receive safe and effective medications. 
2. ERISA	
The Employee Retirement Income Security Act of 1974 (ERISA) is 
a federal law that establishes minimum standards for employer-
sponsored health plans in the private industry (other than churches).99  
ERISA requires plans to: (1) provide participants with plan information; 
(2) imposes fiduciary duties upon those who manage and control the 
health plan; (3) requires the plan to implement a grievance and appeals 
process for participants to access their plan benefits; and (4) provides 
participants with the right of action to sue for benefits and breaches of 
a fiduciary duty.100  ERISA states that a plan shall “specify the basis on 
which payments are made to and from the plan[]” and that the fiduciary 
shall administer the plan “in accordance with the documents and 
instruments governing the plan[.]”101 
 
 96 45 C.F.R. § 156.122(a)(3)(iii)(B-C).  
 97 21 U.S.C. § 812(b)(1). 
 98 42 U.S.C. § 1804(d) (“Nothing in this title shall be construed to preempt any State 
law that does not prevent the application of the provisions of this title.”).	
 99 29 U.S.C. § 1001; ERISA, U.S. DOJ,	 https://www.dol.gov/general/topic/health-
plans/erisa (last visited Feb.. 26, 2021).  
	 100	 ERISA, U.S. DOJ,	 https://www.dol.gov/general/topic/health-plans/erisa (last 
visited Feb. 26, 2021). 
 101 29 U.S.C. §§ 1l02(b)(4), 1l04(a)(1)(D); Egelhoff v. Egelhoff, 532 U.S. 141, 148 
(2001) (quoting Fort Halifax Packing Co. v. Coyne, 482 U.S. 1, 9 (1987)). 
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ERISA preempts all state laws as they “relate to” employer-
sponsored health plans.102  Based on Supreme Court precedent, ERISA’s 
preemption clause should be interpreted broadly to allow for national 
uniformity of rules that apply to employee benefit programs.103  In 
particular, ERISA preempts state laws that: (1) refer specifically to 
ERISA plans (i.e., all private employer-sponsored health plans), (2) 
mandate employee benefit structures or their administration, (3) offer 
different enforcement mechanisms, or (4) constrain employers or plan 
fiduciaries to certain choices or prevent uniform administrative 
practice.104  As such, unless a provision of ERISA explicitly provides 
states with the authority to regulate a particular aspect of an employer-
sponsored plan,105  ERISA preempts state laws that either directly 
regulate employer-sponsored plans (e.g., requiring a plan to offer all 
employees health insurance) or that indirectly impact the plans (e.g., 
regulating a plan’s formulary).106  Additionally, the Supreme Court has 
held that “if an individual, at some point in time, could have brought his 
claim under ERISA [to recover benefits due to him, enforce his rights, or 
clarify his rights under the terms of the plan], and where there is no 
other independent legal duty that is implicated by a defendant’s actions, 
then the individual’s cause of action is completely preempted by 
ERISA[.]”107 
ERISA’s “savings clause” creates an important exception from 
preemption, thereby allowing states to regulate “the business of 
insurance.”108  The savings clause permits states to “regulate traditional 
insurance carriers conducting traditional insurance business.”109  In 
other words, it allows states to regulate the terms and conditions of 
health insurance (e.g., the benefits in a health plan or the rules under 
which the health insurance market must operate).  But, the Supreme 
 
 102 29 U.S.C. § 1144(a) (stating “the provisions of [ERISA] shall supersede any and all 
State laws insofar as they may now or hereafter related to any employee benefit 
plan[.]”). 
 103 Shaw v. Delta Air Lines, 463 U.S. 85, 98 (1983); Metro. Life Ins. Co. v. Mass., 471 
U.S. 724, 732 (1985); Alessi v. Raybestos-Manhattan, Inc. 451 U.S. 504, 524 (1981). 
	 104	 Egelhoff, 532 U.S. at 148; NY State Conf. of Blue Cross & Blue Shield Plans v. 
Travelers Ins. Co., 514 U.S. 645, 658 (1995); Ingersoll-Rand Co. v. McClendon, 498 U.S. 
133, 142 (1990); Fort Halifax Packing Co. v. Coyne, 482 U.S. 1, 14 (1987). 
	 105	 See,	e.g., 42 U.S.C. § 300gg-22(a)(1). 
	 106	 ERISA	 Preemption	 Primer, THE AUTISM CMTY. IN ACTION,	 http://tacanow.org/wp-
content/uploads/2011/03/erisa-preemption-primer.pdf (last visited Feb. 26, 2021). 
 107 Aetna Health Inc. v. Davila, 542 U.S. 200, 210 (2004); see	also Conn. State Dental 
Ass’n v. Anthem Health Plans, Inc., 591 F.3d 1337, 1345 (11th Cir. 2009) (“The Davila test 
thus requires two inquiries: (1) whether the plaintiff could have brought its claim under 
§ 502(a); and (2) whether no other legal duty supports the plaintiff’s claim.”). 
 108 29 U.S.C. § 1144(b)(2)(A). 
	 109	 ERISA	Preemption	Primer, supra	note 106. 
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Court has ruled that ERISA would preempt state law if the state law 
“govern[ed] . . . a central matter of plan administration . . . [or] 
interfere[d] with nationally uniform plan administration.”110  
The savings clause is subject to an exception known as ERISA’s 
“deemer clause.”  The deemer clause provides that employer-sponsored 
self-insured plans (i.e., plans for which the employer provides all of the 
funding and coverage without the assistance of an insurance company) 
are not deemed to be insurance and thus not subject to state 
regulation.111  The deemer clause does not, however, apply to employer-
sponsored fully-insured plans (i.e., plans for which an insurance 
company provides funding).112  As such, while both self-insured and 
fully-funded plans are both subject to ERISA, only fully funded plans 
may be subject to state regulation.   
ERISA would likely prohibit a health plan from providing coverage 
of non-FDA-approved cannabis products.  ERISA imposes a fiduciary 
duty on plan administrators to comply with all federal laws.113  For 
example, in Durand	v.	Hanover	Insurance	Group,114 a plan administrator 
brought suit against the sponsor of an employee pension plan for using 
a methodology to calculate lump-sum distributions that did not comply 
with the law.115  The Sixth Circuit held that ERISA requires that the plan 
administrator act “in accordance with the documents and instruments 
governing the plan insofar as such documents and instruments are 
consistent with [ERISA].”116  The court also noted that the plan 
administrator’s authority to “disregard unlawful plan provisions” was 
“derived from [her] own duty to comply with the law.”117  As previously 
discussed, all non-FDA-approved cannabis products are illicit under the 
CSA and FDCA.118  ERISA would therefore prohibit plan administrators 
from offering payment for or coverage of such products because, in 
doing so, plan administrators would be breaching their fiduciary duty to 
comply with federal laws. 
ERISA also would likely preempt any state law mandating that non-
FDA-approved cannabis products be a covered benefit for both self-
funded plans and fully insured plans.  Pursuant to the deemer clause, 
 
 110 Egelhoff v. Egelhoff, 532 U.S. 141, 148 (2001). 
 111 29 U.S.C. § 1144(b)(2)(B). 
 112 Metro. Life Ins. Co. v. Mass., 471 U.S. 724, 732 (1985). 
	 113	 See	Durand v. Hanover Ins. Grp., Inc., 560 F.3d 436, 442 (6th Cir. 2009).	
	 114	 Id. at 436. 
	 115	 Id.	at 437. 
	 116	 Durand, 560 F.3d	at 442. 
	 117	 Id. 
 118 21 U.S.C. § 812 Schedule 1 (c)(17) (2018); 21 C.F.R. §§ 1308.11(d)(23), (58) 
(2020); 21 U.S.C. § 355(a) (2021); FDA	Regulation	of	CBD, supra	note 7. 
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states may not regulate self-funded employer plans.  Thus, any state law 
mandating coverage of non-FDA-approved cannabis products would 
automatically be invalid as it pertains to self-funded plans.  Additionally, 
such state laws would likely interfere with the nationally uniform plan 
administration of fully insured plans.119  State laws legalizing the use of 
cannabis vary from state-to-state, and at this point, only a handful of 
states have introduced legislation that would mandate health plans to 
cover non-FDA-approved cannabis products as a health benefit.  Plan 
administrators would have to create varying formularies from state-to-
state wherein claims for cannabis coverage or reimbursement would be 
approved in some states but not others.  As such, laws mandating 
coverage would interfere with plan administrators’ ability to administer 
uniform plans nationally.  
3. Workers’	Compensation		
Workers’ compensation programs provide benefits to workers 
who are injured while working, or whose health conditions or 
disabilities were caused or worsened by workplace conditions.120  
Benefits are offered without regard to fault and are often the exclusive 
remedy offered for workplace injuries and illnesses.121  Workers’ 
compensation is usually provided through a network of state 
programs.122  Employers purchase insurance to provide for workers’ 
compensation benefits.123  Federal workers’ compensation laws cover 
federal civilian employees and their dependents, persons engaged in 
maritime employment, seamen, coal miners who develop black lung or 
pneumoconiosis, veterans, and railroad workers.124  State workers’ 
compensation statutes govern most, if not all, other workers.125  Further, 
state workers’ compensation laws and the protections provided vary on 
a state-by-state basis..126  Workers’ compensation typically covers the 
 
	 119	 Gobeille	v.	Liberty	Mut.	Ins.	Co., 136 S. Ct. 936, 943 (2016).  
 120 CONG. RESEARCH SERV., R44580, WORKERS’ COMPENSATION: OVERVIEW AND ISSUES 1, 13 
(2020), https://fas.org/sgp/crs/misc/R44580.pdf.  
	 121	 Id. at 1. 
	 122	 Id. 
	 123	 Id.  
	 124	 See Federal Employees’ Compensation Act, 5 U.S.C. §§ 8101-8193 (2016); 
Longshore and Harbor Workers’ Compensation Act, 33 U.S.C. §§ 901-950 (2020) ; 
Federal Coal Mine Health and Safety Act of 1969, 30 U.S.C. §§ 901-945 (2020); Federal 
Employers’ Liability Act, 45 U.S.C. §§ 51-60 (2020); Veterans’ Benefits Act, 38 U.S.C. § 
1151 (2020).  
 125 CONG. RESEARCH SERV., supra	note 120, at 1 (“The federal government has only a 
limited role in the provision of workers’ compensation because most workers are 
covered by state laws.”). 
	 126	 See CONG. RESEARCH SERV., supra	note 120, at 5-6. 
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cost of clinical visits, laboratory tests, exams, and medications that are 
prescribed to treat an injured or ill employee.127  
Coverage of medical marijuana, in particular, differs from state to 
state, with courts weighing in on whether reimbursement can be 
compelled, given that non-FDA-approved cannabis products are illegal 
under the CSA and FDCA.128  For example, medical marijuana laws 
exempt certain entities, such as health insurers, from reimbursement 
mandates.129  Colorado law provides that “[n]o governmental, private, 
or any other health insurance provider shall be required to be liable for 
any claim for reimbursement for the medical use of marijuana.”130  
These exemptions could also include workers’ compensation plans.  
Additionally, Arizona law explicitly states that nothing in its marijuana 
laws mandates that “a government medical assistance program, a 
private health insurer or a workers compensation carrier or self-
insured employer providing workers compensation benefits to 
reimburse a person for costs associated with the medical use of 
marijuana.”131  Ohio’s Bureau of Workers’ Compensation goes one step 
further and states that it will only cover medications that are FDA 
approved, dispensed from a pharmacy, and on a pharmaceutical 
formulary.132 
 
	 127	 See,	e.g., CAL. LAB. CODE § 4600(a) (2021); Medical	&	Pharmacy	Benefits,	NY STATE 
INS. FUND, https://ww3.nysif.com/Home/Claimant/WCClaimant/ProviderNetworks 
(last visited Feb. 28, 2021); Florida	 Workers’	 Compensation	 Health	 Care	 Provider	




	 128	 See, e.g., Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 17 (Me. 2018) (finding 
that employers were not required to cover medical marijuana under workers’ 
compensation); Appeal of Panaggio, 205 A.3d 1099, 1103 (N.H. 2019) (finding that the 
insurer was required to cover medical marijuana); Vialpando v. Ben’s Auto. Servs., 331 
P.3d 975, 980 (N.M. Ct. App. 2014) (finding that the employer was required to cover 
medical marijuana). 
 129 James Lynch & Lucian McMahon, Haze	of	Confusion:	How	Employers	and	Insurers	
Are	Affected	by	a	Patchwork	of	State	Marijuana	Laws, INS. INFO. INST., 13 (June 2019),	
https://www.iii.org/sites/default/files/docs/pdf/marijuanaandemploy_wp_062019.p
df.  
 130 COLO. CONST. art. XVIII, § 14, (10)(a) (2020); Lynch & McMahon, supra note 129, at 
13. 
 131 ARIZ. REV. STAT. ANN. § 36-2814 (2020); Lynch & McMahon, supra note 129, at 13.  
 132 Lynch & McMahon,	supra	note 129; Medical	Marijuana	and	 Its	 Impact	on	BWC, 
OHIO BUREAU OF WORKERS’ COMPENSATION, 1 (Aug. 2018), 
https://www.bwc.ohio.gov/downloads/blankpdf/MedMarijuanaImpact.pdf. 
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Other states permit coverage of cannabis products.  For example, 
in Petrini	v.	Marcus	Dairy,	Inc.,133 Connecticut’s Workers Compensation 
Commission found that medical marijuana is a “reasonable and 
necessary medical treatment” that is reimbursable.134  Additionally, in 
2015, the Minnesota Department of Labor and Industry promulgated a 
rule that excluded “medical cannabis” from its definition of illegal 
substance so that it could be reimbursed as a medical treatment.135  But, 
laws that would mandate coverage would likely be preempted by 
federal law, as discussed below. 
C. FEDERAL PREEMPTION AND THE CSA 
State laws mandating that health plans or workers’ compensation 
plans cover non-FDA-approved cannabis products will likely be 
preempted by federal laws, such as the CSA, to the extent that such state 
laws conflict with the federal law.  The Supremacy Clause of the U.S. 
Constitution “unambiguously provides that if there is any conflict 
between federal and state law, federal law shall prevail.”136  Federal law 
can preempt state law in three ways: (1) “express preemption, where 
Congress expressly states that the federal law preempts the state law;” 
(2) “field preemption where Congress explicitly or implicitly leaves ‘no 
room’ for state law, or where federal law is ‘so dominant’ that it ‘will be 
assumed to preclude enforcement’ of state law”; and (3) “by conflict 
preemption, where the state law ‘actually conflicts with the federal 
law.’”137 Conflict preemption occurs if “compliance with both federal 
and state [law] is a physical impossibility” because federal and state law 
“irreconcilabl[y] conflict” or if “state law stands as an obstacle to the 
accomplishment and execution of the fully purposes and objectives of 
Congress.”138 
 
The CSA contains specific conflict preemption language. It states:  
 
No provision of this title shall be construed as indicating an 
intent on the part of the Congress to occupy the field in which 
that provision operates, including criminal penalties, to the 
 
 133 Petrini v. Marcus Dairy, Inc., 2016 WL 6659149 (Conn. Work. Comp. May 12, 
2016). 
	 134	 Id. at ¶ H. 
 135 MINN. R. § 5221.6040(7a); Lynch & McMahon,	supra	note 129. 
 136 Gonzales v. Raich, 545 U.S. 1, 29 (2005); see U.S. CONST.  art. VI, cl. 2 (“This 
Constitution, and the Laws of the United States . . . shall be the supreme Law of the 
Land.”). 
 137 Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 14 (Me. 2018). 
	 138	 Id.	 
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exclusion of any State law on the same subject matter which 
would otherwise be within the authority of the State, unless 
there is a positive conflict between that provision of this title 
and that State law so that the two cannot consistently stand 
together.139  
 
In short, the CSA preempts any state law if (1) a conflict exists 
between the CSA and the state law; and (2) compliance with the 
requirements of both is impossible.140  In practice, the CSA likely would 
not preempt state laws that simply allow for (but do not mandate) the 
distribution and possession of marijuana because such laws do not 
require an entity to violate a federal law.  But, the CSA would preempt a 
state law mandating that an entity violates the CSA because the state law 
and the CSA would not be able to “consistently stand together,” as 
established in Bourgoin	v.	Twin	Rivers.141   
1. Case	Law	Supporting	Preemption	
In Bourgoin, the Maine Supreme Court held that covering the cost 
of injured workers’ marijuana qualified as aiding and abetting unlawful 
possession and use of marijuana.142  In that case, the plaintiff sustained 
a work-related injury and was initially prescribed opioids.143  The 
opioids resulted in severe adverse side effects.144  The plaintiff’s 
physician then issued him a certification to use medical marijuana for 
chronic back pain.145  The plaintiff successfully petitioned the workers’ 
compensation board for an order requiring his former employer, the 
defendant, to reimburse him for medical marijuana.146  The court was 
called upon to determine the relationship between the federal CSA and 
the Maine Medical Use of Marijuana Act (MMUMA).147  The court 
concluded that, where an employer is subject to an order that would 
require it to subsidize an employee’s acquisition of medical marijuana, 
there is a positive conflict between federal and state law, and as a result, 
the CSA preempts the MMUMA.148  The court noted that marijuana is a 
Schedule I drug, and therefore, it is illegal to knowingly or intentionally 
 
	 139	 Id.	(citing 21 U.S.C. 903). 
	 140	 Id.	at 15. 
	 141	 Id.	at 20. 
	 142	 Id. 
	 143	 Bourgoin, 187 A.3d at 13. 
	 144	 Id. 
	 145	 Id.  
	 146	 Id.	 
	 147	 Id.  
	 148	 Id. 
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“manufacture, distribute, or dispense, or possess with the intent to 
manufacture, distribute, or dispense” marijuana.149  The MMUMA allows 
a “qualifying patient” to possess a limited amount of marijuana for 
medical use.150  Under the MMUMA, a patient is “qualified” if he or she 
receives a written certification from a professional that he or she “is 
likely to receive therapeutic benefit” from the medical marijuana and 
the medical marijuana used “to treat or alleviate the patient’s 
debilitating medical condition.”151  The CSA and MMUMA conflict 
because under the CSA marijuana has no legitimate medical purposes, 
unlike under the MMUMA, which states that it does.152  As such, the court 
found that it would be impossible to comply with both the CSA and the 
state order to cover medical marijuana as a workers’ compensation 
benefit because complying with the order requires aiding and abetting 
the illegal possession of marijuana; therefore, observing the CSA 
requires violating the MMUMA.153  The court further noted that MMUMA 
does not create a “state right to commit a federal crime” and that “a 
person’s right to use medical marijuana cannot be converted into a 
sword that would require another party, such as [the defendant], to 
engage in conduct that would violate the CSA.”154   
In discussing the employer’s risk of criminal liability, the court 
stated that a federal prosecution can be initiated against a “principal,” 
which is defined as any individual who, among other things, aids or 
abets a crime.155  A party can be liable for aiding and abetting a crime if 
it: (1) took “an affirmative act in furtherance of that offense”, and (2) 
acted “with the intent of facilitating the offense’s commission.”156  
Ultimately, the court found that marijuana is a Schedule I substance 
under the CSA for which it is illegal to “manufacture, distribute, or 
dispense, or possess.”157  Thus, if the defendant were to comply with the 
administrative order and subsidize the plaintiff’s use of medical 
marijuana, the defendant would be engaging in conduct that meets the 
elements of criminal aiding and abetting despite state law allowing 
medical marijuana use.158  The court stated “[a]s invoked against [the 
 
 149 Bourgoin, 187 A.3d at 16. 
	 150	 Id.	 at 18; 22 M.R.S. §§ 2422(9), 2423-A(1) (authorizing the possession of 
marijuana). 
	 151	 Bourgoin, 187 A.3d	at 18. 
	 152	 See	id.	at 18-19. 
	 153	 Id.	at 19. 
	 154	 Id. at 19-20. 
	 155	 Id.	at 17 (citing 18 U.S.C. 2(a)). 
	 156	 Id. (citing Rosemond v. United States, 134 S. Ct. 1240, 1245 (2014)). 
	 157	 Bourgoin, 187 A.3d at 16 (quoting 21 U.S.C.S. § 841(a)(1)). 
	 158	 Id.	at 17. 
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defendant], the MMUMA requires what federal law forbids, and the 
authority ostensibly provided by the Maine law is ‘without effect.’”159  
The court ultimately held that employers are not required to reimburse 
employees for the cost of medical marijuana through workers’ 
compensation programs.160 
Likewise, in In	 re	 Daniel	Wright,161 the Massachusetts Supreme 
Judicial Court was asked to determine whether an insurance company 
can be required to reimburse an employee for medical marijuana 
expenses.162  The claimant sought reimbursement for medical marijuana 
to treat chronic pain resulting from a work-related injury.163  The court 
ruled that marijuana’s status as a federally illicit substance preempted 
the state from ordering a workers’ compensation insurer to cover 
medical marijuana expenses.164  Massachusetts law expressly states that 
“[n]othing in the law requires any health insurer, or any government 
agency or authority, to reimburse any person for the expenses of the 
medical use of marijuana.”165  The court stated “[i]f insurers were 
required to make such payments, the size and scope of the legalization 
of medical marijuana would be substantially expanded, raising concerns 
about federal enforcement and preemption.”166  The court went on to 
state that unlike patients and providers covered by Massachusetts’s 
medical marijuana laws, insurers would “not be participating in the 
patient’s use of a federally proscribed substance voluntarily.”167  The 
risk of federal prosecution for aiding and abetting in the possession and 
distribution of marijuana would involuntarily be imposed upon 
insurers.168  The court noted that insurers are commonly engaged in 
interstate commerce, which increases federal regulators’ concerns of 
CSA violations, and that “[r]equiring interstate insurers to participate in 
the Massachusetts medical marijuana scheme would extend the reach of 
the Massachusetts act well beyond the Commonwealth’s borders.”169 
 
	 159	 Id. at 22 (quoting Mut.	Pharm.	Co.,	Inc.	v.	Bartlett, 570 U.S. 472, 486-87 (2013)). 
	 160	 Id. 
	 161	 In	re	Daniel	Wright, 486 Mass. 98 (2020). 
	 162	 Id. at 98-99. 
	 163	 Id. at 99.  
	 164	 Id. 
	 165	 Id. (quoiting St. 2012, c. 369, §7 (B)). 
	 166	 Wright’s	Case, 486 Mass	at 109. 
	 167	 Id.   
	 168	 Id.	at *21.   
	 169	 Id. 
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2. Improper	Findings	of	No	Preemption		
There are several cases that stand in direct contrast with Bourgoin	
and Wright.  The courts’ rationale in each of these cases was flawed, 
however. 	For example, in McNeary	v.	Freehold	Township,170 a New Jersey 
workers’ compensation judge (WCJ) ruled that the defendant, a self-
insured township, was required to pay for a worker’s medical 
marijuana.171  In that case, the defendant refused to cover the medical 
marijuana treatment for the worker who had muscular spasticity, 
arguing that marijuana was illegal under the CSA and that the CSA 
preempts state law.172  The insurer cited Bourgoin	 for the basis of its 
argument.173  But, the WCJ ruled that the CSA did not preempt the state’s 
medical marijuana law.174  He noted that the CSA and the New Jersey 
Medical Marijuana Act were both intended to deter the distribution and 
use of illicit substances for the purposes of the overall general public 
health.175  The WCJ did not personally believe that deterring the use of 
marijuana for medical purposes achieves the goal of improving general 
public health, however.176  Making his own medical judgement, the WCJ 
stated that medical marijuana “is safer,” “less addictive,” and “better for 
the treatment of pain” than currently marketed opioid analgesics.177  
The WCJ also stated that an insurance carrier could not possess, 
distribute, or intend to distribute marijuana in violation of the CSA by 
providing coverage of the substance.178  
The WCJ in McNeary	 erred because the ruling stands in direct 
conflict with the CSA.  As noted in Bourgoin, the CSA contains no 
 
 170 Order, McNeary v. Freehold Twp., 2008-8094, *1 (N.J. Workers’ Comp. Div., June 
28, 2018). 
	 171	 Id.  
	 172	 McNeary, 2008-8094 at *4, 10, 12. 
	 173	 Id.	at *6. 
	 174	 Id.	at *10. 
	 175	 Id. 
	 176	 Id.	at *11–12 (“I honestly don’t feel in my heart of hearts that this is a conflict. . . . 
What else is important to note here is in this, Mr. McNeary’s case, there is a documented 
medical need and the concern is that Mr. McNeary is going to become addicted to 
opioids, [P]ercocet and others.  And, quite frankly, this Court is very aware of the 
tremendously, the explosion of these narcotics on the streets in the United States in the 
last decade, the tremendous amounts of death and addiction that are associated with 
these opioids.  If there’s anything criminal here, it’s how these drugs have been force fed 
to injured people creating addicts.  I believe, and I think the science supports this, is that 
medical marijuana is safer, it’s less addictive, it is better for the treatment of pain.”).	
	 177	 Id.	at *11. 
	 178	 McNeary, 2008-8094 at *11 (“Certainly I don’t understand how a carrier, who will 
never possess, never distribute, never intend to distribute these products, who will 
nearly sign a check into an attorney’s trust account is in any way complicit with the 
distribution of illicit narcotics.”).	
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exception for medical uses of marijuana.179  Instead, the CSA places 
marijuana in Schedule I, which is reserved for substances with “high 
potential for abuse” and with “no currently accepted medical use in 
treatment in the U.S.”180  Had Congress or the DEA determined that 
marijuana contained accepted medical uses, it would have removed it 
from Schedule I.  As such, any conflict between state law and the CSA 
should be resolved in favor of the CSA.181  Moreover, while an insurer is 
not directly possessing, distributing, or intending to distribute 
marijuana, the WCJ failed to consider whether the insurer could be 
considered aiding and abetting such actions.  Many courts have held that 
defendants can be convicted of aiding and abetting drug transactions 
because they “contribute to” or “further” such transactions by providing 
the “purchase money” for the illicit substances at issue.182  
Like the WCJ in McNeary, the Court of Appeals of the State of New 
Mexico in Vialpando	 v.	 Ben’s	 Automotive	 Services183 upheld an order 
requiring an employer to reimburse an employee for medical marijuana 
treatment.184  In this case, an employee sustained a low back injury.185  
He filed for workers’ compensation to cover medical marijuana after his 
health care provider certified that his severe chronic pain was 
debilitating.186  The WCJ granted his order pursuant to the state’s 
Compassionate Use Act (CUA).187  On appeal, the employer argued that 
it would be illegal and unenforceable under federal law to reimburse for 
medical marijuana.188  The employer further argued that the CUA did not 
require reimbursement for medical marijuana.189  The court held that 
the CUA did authorize reimbursement for medical marijuana, noting 
that the CUA required employers to provide injured workers with 
“reasonable and necessary health care services from a health care 
provider.”190  The court agreed with the WCJ’s determination that the 
employee’s “participation in a course of cannabis in the New Mexico 
[M]edical Cannabis Program would constitute reasonable and necessary 
 
 179 Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 15 (Me. Sup. Jud. Ct. 2018); see	
also	Gonzales v. Raich, 545 U.S. 1, 27–28 (2005). 
 180 21 U.S.C. § 812(b)(1). 
	 181	 See Gonzales, 545 U.S. at 29. 
	 182	 See,	e.g., United States v. Garcia-Benites, 702 F. App’x 818, 822 (11th Cir. 2017);	
United States v. Tenorio, 360 F.3d 491, 495 (5th Cir. 2004). 
 183 Vialpando v. Ben’s Auto. Serv., 331 P.3d 975 (N.M. App. Ct. 2014). 
	 184	 Id.at 976. 
	 185	 Id. 
	 186	 Id.	at 977. 
	 187	 Id.	 
	 188	 Id.	at 976. 
	 189	 Vialpando, 331 P.3d at 976. 
	 190	 Id.	at 977. 
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services,” as established by employee’s medical necessity certification 
form from his health care provider.191  
The employer argued that the WCJ’s order was illegal because it 
was contrary to the CSA.192  The court acknowledged that the CSA 
classifies marijuana as a Schedule I controlled substance and that any 
conflict between the CSA and the CUA should be resolved in favor of the 
CSA.193  The court found, however, that in this case, the employer was 
not attempting to challenge the legality of the CUA.194  While the 
employer asserted that the order to reimburse the employee’s medical 
marijuana “essentially requires” the employer to commit a federal 
crime, the court also stated that the employer failed to cite to any federal 
statute it would be forced to violate.195  The McNeary	court therefore 
ruled in favor of the plaintiff based on failure to plead proper arguments, 
like the arguments made in Bourgoin	and Wright.196  
In Lewis	 v.	 American	 General	 Media,197 New Mexico’s CUA was 
challenged.198  In that case, another worker who was certified to receive 
treatment with medical marijuana sought and received reimbursement 
through workers’ compensation.199  The employer challenged a WCJ’s 
finding that there was sufficient evidence to support reimbursement for 
the marijuana.200  Among other things, the employer argued that the 
CUA conflicted with the CSA.201  While the court acknowledged that the 
CSA conflicted with the CUA in that the CSA did not except marijuana use 
for medical purposes, it still declined to reverse the WCJ’s order.202  The 
court noted that then Deputy Attorney General James M. Cole had issued 
a federal memorandum (referred to as the “Cole Memo”) with the U.S. 
Department of Justice’s (DOJ) position on marijuana enforcement.203  
The Cole Memo affirmed that marijuana is illegal under the CSA but did 
not identify enforcement against medical marijuana users as a 
priority.204  Instead, the Cole Memo noted that the DOJ “would generally 
 
	 191	 Id.	at 977-78. 
	 192	 Id.	at 979. 
	 193	 Id. 
	 194	 Id.	at 979-980. 
	 195	 Vialpando, 331 P.3d at 980. 
	 196	 See	id.  
 197 Lewis v. Am. Gen. Media, 355 P.3d 850 (N.M. App. Ct. 2015). 
	 198	 Id.	at 851. 
	 199	 Id.	at 852. 
	 200	 Id. 
	 201	 Id.	 
	 202	 Id.	 
	 203	 Lewis, 355 P.3d at 857. 
	 204	 Id. 
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defer to state and local authorities.”205  While the employer argued that 
it would be aiding and abetting in a violation of the CSA, the court ruled 
that the employer would likely not face liability based on the DOJ’s 
position laid out in the Cole Memo.206  
The court in Lewis	also erred.  While the Cole Memo allowed for 
discretionary enforcement of the federal law, a conflict between state 
and federal law, nevertheless, still exists.  Preemption is based upon the 
black letter of the law rather than the likelihood of whether that law will 
be enforced.207  The Cole memo did not challenge the existence of the 
CSA, but merely instituted an internal policy regarding enforcement.208  
As stated in Bourgoin, “[p]rosecuted or not, the fact remains that [the 
insurer] would be forced to commit a federal crime if it complied with 
the directive of” a state law mandate of medical marijuana coverage; the 
“magnitude of the risk of criminal prosecution is immaterial.”209  As 
noted in Wright, reliance on an internal federal policy is misplaced 
because such policies are transitory.210  For example, the current 
Administration revoked the Cole Memo in its entirety.211  
In Hager	 v.	 M&K	 Construction,212 the Appellate Division of the 
Superior Court of New Jersey also held that a WCJ “can order an 
employer to reimburse its employee for the employee’s use of medical 
marijuana prescribed for chronic pain following a work-related 
accident.”213  Similar to Bourgoin, the employer argued that the New 
Jersey Compassionate Use Medical Marijuana Act (MMA) was 
preempted by the CSA and that the employer would be aiding and 
abetting in a violation of the CSA by reimbursing the employee for his 
marijuana use.214  Here, as in McNeary, the court determined that the 
 
	 205	 Id.	 
	 206	 Id.	at 859. 
	 207	 See	Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 21 (Me. Sup. Jud. Ct. 2018) 
(referring to the “Ogden Memo,” a predecessor to the Cole Memo). 
	 208	 See	id.	 
	 209	 See	id. 
	 210	 In	 re	 Daniel	Wright, SJC-12873 at *12-13 ([“T]he Department of Justice has 
reversed its own stance toward the prosecution of medical marijuana cases multiple 
times.  The Department of Justice issued a series of memoranda during the 
administration of President Barack Obama advising Federal prosecutors not to 
prioritize the prosecution of individuals engaged in marijuana-related activities 
pursuant to a State medical marijuana law. . . .  This guidance was later rescinded under 
the administration of President Donald Trump.”). 
 211 Memorandum from the Attorney General on Marijuana Enforcement (Jan. 4, 
2018), available	 at https://www.justice.gov/opa/press-
release/file/1022196/download.   
 212 Hager v. M&K Const., 462 N.J. Super. 146 (App. Div. 2020). 
	 213	 Id.	at 152. 
	 214	 Id. 
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WCJ’s order does not require the employer to possess, manufacture, or 
distribute marijuana, and therefore, there is no conflict between the 
MMA and the CSA.215  The court further held that the employer lacked 
the specific intent required to aid and abet in an offense under federal 
law, and that “one cannot aid and abet a completed crime.”216  The court 
reasoned that the employer was simply paying for the employee’s 
medical expense and not purchasing or distributing marijuana on the 
employee’s behalf, and that the employee obtained the drug prior to the 
reimbursement.217  The court further held that the employer was not an 
active participant in the commission of a crime but rather merely 
complying with state law.218 
The arguments in Hager	are flawed.  First, as established, while the 
employer is not directly possessing, manufacturing, or distributing 
marijuana, it is aiding and abetting in the possession of marijuana if it 
reimburses for such products.  The court is incorrect in reasoning that 
the employer lacks “intent” to aid and abet.  As set forth in Rosemond	v.	
United	States,219 “for purposes of aiding and abetting law, a person who 
actively participates in a criminal scheme knowing its extent and 
character intends that scheme’s commission,” and on that basis, is 
criminally liable.220  An employer knowingly violates the CSA by 
reimbursing for marijuana because the employer is required to submit 
all workers’ compensation claims for processing.  Thus, the employer is 
not just paying for expenses in a black box; the employer is fully aware 
that the employee is seeking to possess marijuana in violation of the 
CSA.  As such, in reimbursing for the marijuana, the employer is aiding 
in the commission of the crime.  Moreover, it cannot be a defense to a 
federal law that a party complied with a state law; otherwise, the 
preemption doctrine would be reversed, and states could completely 
disregard federal criminal law.  Finally, it is inaccurate to state that an 
insurer or employer would not aid and abet by reimbursing the cost of 
marijuana after it has been purchased because it is impossible to aid and 
abet a completed crime.  By offering coverage of marijuana as a workers’ 
compensation or health benefit, an insurer is making a future promise 
to reimburse marijuana costs.  Because courts have held that a promise 
of future payment is equivalent to payment before the fact, the payment 
 
	 215	 Id. at 153. 
	 216	 Id.	at 166. 
	 217	 Id.	 
	 218	 Hager, 462 N.J. Super. at 166. 
 219 Rosemond v. United States, 572 U.S. 65 (2014). 
	 220	 Id. at 77. 
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itself furthers the crime’s commission.221  The promise of payment for 
marijuana expenses, therefore, encourages the crime of marijuana 
possession.	
Other courts have danced around the issue of federal preemption.  
For example, in In	 re	WDF	 Inc.,222 New York Workers’ Compensation 
Board determined that medical marijuana is reimbursable if certain 
criteria are met.223  It noted that the state’s Public Health Law (“Medical 
Use of Marijuana”) permits marijuana to be “prescribed” to treat several 
medical conditions and that the state law is not preempted merely 
because the law had not yet been invalidated by the Second Circuit or 
the New York Court of Appeals under federal preemption doctrine.224  
Likewise, in Appeal	of	Andrew	Panaggio,225 the New Hampshire Supreme 
Court determined that the lower court erred when it held that the state’s 
workers’ compensation law prohibited an insurer from reimbursing for 
medical marijuana because marijuana treatment was “reasonable, 
medically necessary and causally related to [the] work injury.”226  The 
court remanded the case so the lower court could determine whether 
reimbursement would violate federal laws.227  
One could argue that state laws requiring coverage of marijuana 
products, including cannabis-derived CBD containing more than 0.3 
percent THC, similar to the ones proposed in New Jersey, New York, and 
Hawaii, would violate the CSA for the reasons discussed in Bourgoin	and 
Wright.  The CSA would preempt those laws because they require 
insurers and employers to take an action in violation of the CSA.  The 
state law and the CSA “cannot consistently stand together.”228  
Moreover, such laws would require insurers or employers to commit the 
federal crime of aiding and abetting marijuana possession.   
D. FDCA  
State laws mandating the coverage of non-FDA-approved cannabis 
products undermine the purpose and intent of the FDCA, thereby posing 
a risk to public health and safety.  
 
	 221	 See,	e.g., United States. v. Camargo-Vergara, 57 F.3d 993, 1001 (11th Cir. 1995); 
United States. v. Mitchell, 944 F.3d 116, 120 (3d Cir. 2019). 
 222 2017 NY Wrk Comp G1403803 (N.Y. Workers’ Comp. Bd. June 6, 2017). 
	 223	 Id. 
	 224	 Id. 
	 225	 In	Re Panaggio, 205 A.3d 1099 (N.H. Sup. Ct. 2019).  
	 226	 Id. at 1103. 
	 227	 Id.	at 1105.  A subsequent opinion from the remand is not available at the time of 
writing.  
	 228	 Bourgoin,	187 A.3d at 20 (citing 21 U.S.C. 903) 
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1. Unapproved	New	Drugs	and	Misbranded	Drugs			
State laws mandating the coverage of non-FDA-approved cannabis 
products promote the violation of the FDCA.  As explained above, when 
intended for use as a “drug” (i.e., to diagnose, cure, mitigate, treat, or 
prevent disease),229 cannabis products must obtain FDA approval 
before they can be marketed or distributed in interstate commerce.230  
To date, the FDA has approved one cannabis-derived product and three 
synthetic cannabis-related drug products.231  To the extent that they are 
used, or intended for use, to treat a medical condition, all other non-
FDA-approved cannabis products are considered unapproved new 
drugs and are illegal under the FDCA.232  Unapproved new drugs create 
significant risks to patients because the FDA has not reviewed such 
substances for safety, effectiveness, or quality.233 
In recent years, the FDA has engaged in enforcement actions 
against parties that manufacture, distribute, market, or sell non-FDA-
approved cannabis products.234  State medical marijuana laws that allow 
for the distribution, sale, and possession of non-FDA-approved cannabis 
products are in direct conflict with the FDCA because they permit 
parties to introduce, or cause to be introduced, non-FDA-approved and 
misbranded products into interstate commerce if a health care provider 
certifies that a patient has a legitimate medical need for such products. 
 
 229 21 U.S.C. § 321 (g)(1)(B). 
	 230	 See	21 U.S.C. § 321(g)(1). 
 231 Those products are Epidiolex (cannabidiol), Marinol (dronabinol), Syndros 
(dronabinol), and Cesamet (nabilone). FDA	and	Cannabis:	Research	and	Drug	Approval	
Process, FDA,	 https://www.fda.gov/news-events/public-health-focus/fda-and-
cannabis-research-and-drug-approval-process (last updated Oct. 1, 2020). 
	 232	 What	You	Need	to	Know	(And	What	We’re	Working	to	Find	Out), supra	note 12.  The 
FDA “permits some unapproved drugs to be marketed if: 
The drug is subject to an open drug efficacy study implementation (DESI) 
program proceeding, 
1) Health care professionals rely on the drug to treat serious medical 
conditions when there is no FDA-approved drug to treat the 
condition,  
2) There is insufficient supply of an FDA-approved drug. 
3) The law allows some unapproved prescription drugs to be lawfully 
marketed if they meet the criteria of generally recognized as safe and 
effective (GRASE) or grandfathered.  But, the agency is not aware of 
any human prescription drug that is lawfully marketed as 
grandfathered.”  Unapproved	 Drugs, FDA, (Oct. 26, 2020), 
https://www.fda.gov/drugs/enforcement-activities-
fda/unapproved-drugs. 
 233 21 U.S.C. § 393(b)(2); Unapproved	Drugs, supra	note 232. 
	 234	 FDA	Warns	15	Companies, supra	note 5. 
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Under the FDCA, the FDA has sole authority over drug approval and 
labeling.235  Yet, state medical marijuana laws effectively allow states to 
make their own judgments about a drug’s safety and efficacy.  Some 
states even have a list of medical conditions for which the law is 
applicable.236  These laws thereby stand in conflict with the FDCA.237  
State law cannot “stand[] as an obstacle to the accomplishment and 
execution of the full purposes and objectives of Congress.”238  For 
example, in Zogenix,	Inc.	v.	Patrick,239 the United States District Court for 
the District of Massachusetts found that the FDCA preempted a state 
order banning an FDA-approved drug.240  In that case, the court noted 
that while a state’s police powers permit it to regulate the 
administration of drugs by the health professionals, the state may not 
exercise those powers in a way that is inconsistent with federal law, 
including the FDCA’s objective that safe and effective drugs be available 
to the public.241  
Likewise, in Ouellette	 v.	 Mills,242 the U.S. District Court for the 
District of Maine held that the FDCA preempted a state law permitting 
the importation of foreign drugs that the FDA had not approved.243  The 
state had passed a law to allow Maine residents to import prescription 
drugs from international mail order pharmacies.244  The court noted, 
however, that the FDCA “prohibits the importation or introduction into 
interstate commerce of any ‘new drug’ that has not received FDA 
approval.”245  Similarly, states that permit distribution and possession 
of non-FDA-approved cannabis products directly conflict with the FDCA 
by promoting the distribution of products that the FDA has not deemed 
to be safe and effective. 
State laws mandating coverage of non-FDA-approved cannabis 
products further the notion that these products are safe and effective to 
 
 235 Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 486 (2013); see,	 e.g., Zogenix, Inc. v. 
Patrick, 2014 WL 1454696, at *1 (D. Mass. Apr. 15, 2014) (holding state order banning 
drugs which FDA had approved was preempted); Ouellette v. Mills, 91 F. Supp. 3d 1, 4 
(D. Me. 2015) (holding state law permitting importation of foreign drugs FDA had not 
approved was preempted). 
	 236	 State	Medical	Marijuana	Laws, supra	note 1. 
 237 Bartlett, 570 U.S. at 486; see,	e.g., Zogenix, 2014 WL 1454696 at *1; Ouellette, 91 F. 
Supp. 3d at 4. 
 238 Arizona v. United States, 567 U.S. 387, 399 (2012). 
 239 Zogenix, Inc. v. Patrick, 2014 WL 1454696, at *1 (D. Mass. Apr. 15, 2014). 
	 240	 Id. at *1. 
	 241	 Id.	at *4. 
 242 Ouellette v. Mills, 91 F. Supp. 3d 1, 4 (D. Me. 2015).  
	 243	 Id. 
	 244	 Id. 
	 245	 Id.	at 5. 
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treat medical conditions, despite the lack of approval.  The FDA has 
stated that more clinical trials are needed to study and assess the safety 
and efficacy of cannabis products to treat medical conditions.246  Yet, 
state coverage mandates authorize health plans to reimburse patients 
who use such products for treatment purposes.  In doing so, these 
coverage mandates create and promote a market for unapproved and 
unlawful drugs.  Health care practitioners may direct their patients to 
purchase non-FDA-approved cannabis products, knowing that such 
products will be covered.  These patients may not have otherwise 
purchased such products, and instead, may have been prescribed FDA-
approved drugs proven to be safe and effective in treating their 
conditions.  As such, these state mandates would create an incentive for 
patients to purchase and use unregulated substances that are 
potentially unsafe and ineffective and that are sold by entities who 
violate the FDCA.  
Additionally, these state laws would incentivize the purchase of 
drugs that are often deceptively marketed, given that many 
manufacturers of cannabis products have misleadingly advertised their 
products with therapeutic claims, stating that such products can treat, 
mitigate, or even cure certain health conditions.  Making such 
misleading claims is a violation of the FDCA.247  Currently, rigorous 
scientific data does not exist to establish that these non-FDA-approved 
cannabis products are effective in treating the medical conditions that 
they claim to treat.248  For example, in April 2020, the FDA issued a 
warning letter to Homero Corp. for marketing its CBD products as 
dietary supplements in violation of the FDCA.249  The FDCA states that if 
a product contains an active ingredient in a drug product that has been 
FDA-approved, then it does not meet the definition of dietary 
supplement.250  Additionally, Homero made claims that their non-FDA-
approved CBD products could be used to diagnose, cure, mitigate, treat, 
or prevent a disease.251  In particular, Homero’s website stated that its 
CBD products could “alleviat[e] severe withdrawal symptoms 
associated with opiate dependency,” and could be used to treat AIDS, 
 
	 246	 FDA	Regulation	of	CBD, supra	note 7. 
	 247	 FDA	Warns	15	Companies, supra	note 5. 
	 248	 FDA	and	Cannabis:	Research	and	Drug	Approval	Process, supra	note 231. 




 250 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 321(ff)(3)(B)(i), (ii); Warning	
Letter:	Homero	Corp	DBA	Natures	CBD	Oil	Distribution, supra	note 249. 
	 251	 Warning	Letter:	Homero	Corp	DBA	Natures	CBD	Oil	Distribution, supra	note 249. 
WORTHY (DO NOT DELETE) 4/27/2021  11:16 PM 
410 SETON	HALL	LEGISLATIVE	JOURNAL [Vol. 45:2 
Alzheimer’s Disease, autism, cancer, diabetes, heart disease, kidney 
disease, Parkinson’s disease, and others.252  Yet, the FDA noted that 
Homero’s CBD products were not generally recognized as safe and 
effective for the aforementioned uses, and therefore, the products were 
considered “new drugs.”253  New drugs may not be legally introduced 
into interstate commerce without prior approval from the FDA.254  
These deceptive marketing activities provide consumers with a false 
sense of security that the products they are taking are safe and beneficial 
to their health. 
2. General	Safety	and	Efficacy	Concerns		
The FDA has stated that non-FDA-approved cannabis products 
“can have unpredictable and unintended consequences, including 
serious safety risks” and that “there has been no FDA review of data 
from rigorous clinical trials to support that . . . unapproved products are 
safe and efficacious.”255  Recent studies support the FDA’s statements.  
Given that non-FDA-approved cannabis products are not required to go 
through rigorous safety and efficacy protocols and lack standards for 
quality, purity, and dosage, many have been found to be adulterated 
with undisclosed substances, including high levels of THC, heavy metals, 
toxins, and mold.  For example, one study found synthetic, psychoactive 
adulterants, such as “spice” / “K2,” and other dangerous illicit 
substances in one third of the CBD vape oils that it tested.256  Another 
study from 2019 showed that 70 percent of the CBD products tested 
were “highly contaminated” with heavy metals, such as lead and arsenic, 
herbicides, and pesticides.257  Additionally, an FDA study published in 
July 2020 found that 49 percent of tested CBD products had THC levels 
above the Limit of Quantification.258  A different study published in 2020 
 
	 252	 Warning	Letter:	Homero	Corp	DBA	Natures	CBD	Oil	Distribution, supra	note 249. 
 253 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 331(d), 355(a); Warning	Letter:	
Homero	Corp	DBA	Natures	CBD	Oil	Distribution, supra	note 249. 
 254 21 U.S.C. § 355(a). 
	 255	 FDA	and	Cannabis:	Research	and	Drug	Approval	Process, supra	note 249. 
 256 Holbrook Mohr, Some	CBD	Vapes	Contain	Street	Drug	Instead	of	the	Real	Thing, 
AP NEWS (Sept. 16, 2019),	https://apnews.com/article/7b452f4af90b4 620ab0ff0eb 
2cca62cc.  
 257 Fletcher, supra	note 14. 
	 258	 Sampling	Study	of	 the	Current	Cannabidiol	Marketplace	 to	Determine	 the	Extent	
that	Products	are	Mislabeled	or	Adulterated, U.S Food and Drug Administration, 6 (2020),	
https://aimedalliance.org/wp-content/uploads/2020/07/CBD-Marketplace-
Sampling_RTC_FY20_Final.pdf. 
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showed that 27 percent of the leading CBD brand products contain 
dosages that differ from what is indicated on their labels.259  
A recent survey highlighting consumer confusion about CBD 
products is also concerning.  It found that 21 percent of respondents 
said they continue to take more of their CBD product of choice until they 
“feel something,” 15 percent said they “estimated” their dosages, and 15 
percent said they were not sure of how much they took.260  Only half of 
respondents said they referred to the product labels on dosage.261  If 
these products contain high levels of THC or other harmful adulterants 
and consumers are taking more than the recommended dose, they could 
experience harmful side effects.  For example, the FDA recently stated 
that CBD toxicity could result in such adverse events as liver injury, 
interactions with other drugs, drowsiness, diarrhea, and changes in 
mood.262  Additionally, the United States Army issued a public health 
warning in 2018 after approximately sixty people over the course of a 
few months presented health issues linked to adulterated CBD products 
at medical centers at two bases in North Carolina.263  Symptoms 
included headaches, nausea, vomiting, disorientation, agitation, and 
seizures.264  A few months later, North Carolina health officials issued 
their own warning after approximately thirty people presented in the 
emergency departments with hallucinations, loss of consciousness, and 
heart irregularities linked to adulterated CBD.265  
Similarly, the Nevada Department of Taxation recently issued a 
public health and safety advisory because it identified several non-FDA-
approved cannabis products (i.e., raw cannabis buds and raw cannabis 
in pre-rolled cigarettes) that contained yeast, mold, bacteria, and fungi, 
which are particularly dangerous to consumers with suppressed 
 
 259 Maria Loreto, Leading	CBD	Brands	 Still	Have	 Some	 Inaccurate	Dosages,	Even	 If	
Their	 Numbers	 Have	 Improved, CHICAGO TRIBUNE (June 17, 2020),	
https://www.chicagotribune.com/marijuana/sns-tft-cbd-inaccurate-dosages-
20200617-vizdcxchijbqbpf5ofqvbvjtcm-story.html. 
 260 Hank Schultz, Research	Confirming	Consumers’	Confusion	Points	to	Yawning	Gap	in	
CBD	 Market	 Surveillance, NUTRA (May 21, 2020),	 https://www.nutraingredients-
usa.com/Article/2020/05/21/Research-confirming-consumers-confusion-points-to-
yawning-gap-in-CBD-market-surveillance. 
	 261	 Id. 
	 262	 FDA	Warns	15	Companies, supra	note 5. 
 263 Mark Hay, Everything	We	Know	About	the	Health	Risks	of	Vaping	CBD,	VICE, Aug. 
27, 2018, https://tonic.vice.com/en_us/article/zmk55a/everything-we-know-about-
the-health-risks-of-vaping-cbd; Public	Health	Alert:	Health	Effects	of	Vape	Oils	Containing	
Unknown	 Substances, ARMY PUB. HEALTH CTR., Aug. 31, 2020, 
https://phc.amedd.army.mil/topics/healthyliving/tfl/Pages/VapeOils.aspx.   
 264 Hay, supra	note 263. 
 265 Hay, supra	note 263. 
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immune systems.266  These products had been sold legally at thirty 
dispensaries within the state.267  Likewise, a Hawaii Department of 
Health whistleblower identified a lack of proper controls over Hawaii’s 
marijuana dispensaries.268  The whistleblower, a board-certified 
cannabis physician in the state, noted that at least a third of his patients 
reported safety concerns with vaping cartridges containing THC oils 
purchased from state-regulated shops.269  Tests of the oils showed 
dangerously high concentrations of ethanoyl (e.g., ten times the ethanol 
allowed in Colorado), which can cause eye, lung, nose, and throat 
irritation among other harms.270  
E. DRUG-FREE WORKPLACE ACT 
Non-FDA-approved cannabis products also pose a risk for 
employers because they could result in impairment in the workplace.  
According to the National Alliance of Healthcare Purchasers Coalition, 
“THC in cannabis has an intoxicating effect that can affect an individual’s 
motor skills, reaction time, and coordination at low levels (as little as 2.5 
milligrams to 5 milligrams).”271   
If an employee is impaired in the workplace, the employer may face 
liability, including loss of federal contracts, under the Drug-Free 
Workplace Act of 1988 (DFWA).272  Under the DFWA, employers that 
have entered into federal contracts, or who have received federal grants, 
must make good faith efforts to maintain a drug-free workplace.273  If 
they receive more than $25,000, then they must also provide 
 
	 266	 Public	Health	and	Safety	Advisory	2020‐05, STATE OF NEV., DEP’T OF TAXATION, Feb. 
21, 2020, https://tax.nv.gov/uploadedFiles/tax.nv.gov/ Content/MME/ Public% 
20Health%20and%20Safety%20Advisory%20Cannex%202020-05%20(006).pdf; 
Jenny Kane, Another	Marijuana	Health	Advisory	Issued	for	Products	Sold	at	30	
Dispensaries	in	Nevada, RENO GAZETTE JOURNAL, Feb. 24, 2020,	
https://www.rgj.com/story/news/marijuana/2020/02/24/nevada-dispensaries-
sold-tainted-marijuana-pot-health-advisory-issued/4857545002/.   
	 267	 Id.  
 268 Allyson Blair, State‐Regulated	Marijuana	Vape	Cartridges	Aren’t	Safe,	Doctor	and	
Whistleblower	 Say, HAWAII NEWS NOW, June 3, 2020, 
https://www.hawaiinewsnow.com/2020/06/03/state-regulated-marijuana-vape-
cartridges-arent-safe-doctor-whistleblower-say/.  
	 269	 Id. 
	 270	 Id. 
	 271	 Clinical	 Brief:	 Medicinal	 Uses	 of	 Cannabis‐Derived	 Products, NAT’L ALLIANCE OF 
HEALTHCARE PURCHASER COALITIONS, https://www.nationalalliancehealth.org/resources-
new (last visited March 13, 2021). 
 272 George Fitting, Careless	 Conflicts:	Medical	Marijuana	 Implications	 for	Employer	
Liability	in	the	Wake	of	Vialpando	v.	Ben’s	Automotive	Services, 102 IOWA L. REV. 259, 269 
(2016).  
 273 41 U.S.C. §§ 8102–8103.  
WORTHY (DO NOT DELETE) 4/27/2021  11:16 PM 
2021]	 DAZED	AND	CONFUSED 413 
certification of such efforts.274  If the employer is unable to make such 
good faith efforts, it is considered to be in material breach of its contract; 
payments may be suspended, the contract may be terminated, and the 
contractor can be suspended or debarred as a government 
contractor.275  If the employer makes a false certification regarding its 
good faith efforts, it may be subject to federal prosecution.276  “Drug-free 
workplace” is defined as “a site of an entity (A) for the performance of 
work done in connection with a specific contract or grant . . .; and (B) at 
which employees of the entity are prohibited from engaging in the 
unlawful manufacture, distribution, dispensation, possession, or use of 
a controlled substance.”277  
Given that non-FDA-approved cannabis products are illegal under 
the CSA, use of such products would be considered unlawful under the 
DFWA, triggering certain remediation steps by the employer (e.g., 
encouraging drug counseling, rehabilitation, or use of employee 
assistance program, or imposing penalties on the employee for drug 
abuse violations).278  If the employer is required to cover such products 
through a health plan or workers’ compensation, however, it is unlikely 
the employer could certify that it is making a good faith effort to 
maintain a drug-free workplace.  While employers could require 
employees to only use such substances while they are not working, the 
substances may still remain in the employees’ systems even when they 
are working.279  Consequently, a drug test may not be able to distinguish 
between on-site and off-site drug use.  Additionally, a recent study 
showed that drug testing methodology often cannot distinguish 
between CBD and THC even if THC levels within the CBD product are no 
more than 0.3 percent – the cutoff concentration for a product to 
become illegal marijuana rather than legal hemp.280  Furthermore, in 
University	of	Hawai’i	Professional	Assembly	 v.	Tomasu281 the Supreme 
Court of the State of Hawaii found that to comply with the DFWA 
employers must both have a policy against drug use and implement that 
 
 274 18 C.F.R. § 1316.7. 
 275 18 C.F.R. § 1316.7. 
 276 18 C.F.R. § 1316.7. 
 277 41 U.S.C. § 8101(a)(5). 
 278 41 U.S.C. §§ 8101(a)(1), 8102(a)(1), 8104. 
 279 Priyamvada Sharma, et. al., Chemistry,	Metabolism,	and	Toxicology	of	Cannabis:	
Clinical	Implications, 7(4) IRAN J. PSYCHIATRY 149, 153 (2012) (“The half-life of [THC] for 
an infrequent user is 1.3 days and for frequent users 5-13 days.”).   
 280 Amanda Chicago Lewis, CBD	or	THC?	Common	Drug	Test	Can’t	Tell	the	Difference, 
N.Y. TIMES (Oct. 15, 2019),	 https://www.nytimes.com/2019/10/15/science/cbd-thc-
cannabis-cannabidiol.html.  
 281 Univ. of Haw. Prof’l Assembly v. Tomasu, 900 P.2d 161 (Haw. 1995). 
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policy by engaging in affirmative disciplinary action against an 
employee who fails a drug test.282  The DFWA does not contain any 
exceptions for employers bound by state law.283 
F. OCCUPATIONAL SAFETY AND HEALTH ACT  
State laws mandating coverage of non-FDA-approved cannabis 
products could also expose employers to liability under the 
Occupational Safety and Health Act of 1970 (OSH Act) if employees are 
impaired.  The OSH Act imposes a general duty on employers to “furnish 
to each of his employees employment and a place of employment which 
are free from recognized hazards that are causing or are likely to cause 
death or serious physical harm to his employees” (“General Duty 
Clause”).284  The Occupational Safety and Health Administration (OSHA) 
has strongly supported “measures that contribute to a drug-free 
environment and reasonable programs of drug testing within a 
comprehensive workplace program for certain workplace 
environments, such as those involving safety-sensitive duties like 
operating machinery.”285   
While the OSH Act and its implementing regulations do not 
explicitly require a drug-free workplace, OSHA has stated that, in some 
situations, OSHA’s General Duty Clause may be applicable “where a 
particular hazard is not address by any OSHA standard.”286  OSHA has 
stated that the four components of the General Duty Clause are:  
(1) the employer failed to keep its workplace free of a 
“hazard;” (2) the hazard was “recognized” either by the 
cited employer individually or by the employer’s industry 
generally; (3) the recognized hazard was causing or was 
likely to cause death or serious physical harm; and (4) 
there was a feasible means available that would eliminate 
or materially reduce the hazard.287  
 
 
	 282	 Id.	at 169–70 (“[M]ere promulgation of a policy that proclaims compliance with a 
federal statute will not constitute compliance with that statute . . . . [T]he DFWA 
inherently mandates implementation[.]”); Fitting, supra	note 272, at 269. 
 283 Fitting, supra	note 272, at 269. 
 284 29 U.S.C. § 654(a)(1). 
 285 Letter from John B. Miles, Director of Enforcement Programs, Occupational Health 
and Safety Administration to Patrick J. Robinson, Safety Coordinator, Starline 
Manufacturing Co., Inc., (May 2, 1998), OSHA ARCHIVE, https://www.osha.gov/laws-
regs/standardinterpretations/1998-05-02.  
 286 29 U.S.C. § 654(a)(1); Letter from John B. Miles to Patrick J. Robinson, supra	note 
285. 
 287 Letter from John B. Miles to Patrick J. Robinson, supra	note 285. 
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The duty only arises if all four elements are present.288  Violations of the 
OSH Act may include a civil penalty ranging from $5,000 to $70,000 and 
imprisonment.289 
If an employer must cover non-FDA-approved cannabis products 
and employees are impaired while in the workplace, then the workplace 
may not be free of hazard.  The risk of impairment from marijuana use 
is generally recognized in industries with safety-sensitive positions.  For 
example, a 2019 survey from the National Safety Council (NSC) showed 
that 81 percent of employers were concerned about marijuana having a 
negative impact on their workforce.290  As a result, the NCS has stated 
that no amount of marijuana or other THC products should be allowed 
for employees working in safety-sensitive positions given the impact of 
cannabis on the worker’s psychomotor skills and cognitive ability.291  
Additionally, serious physical harm or death is foreseeable when an 
impaired employee completes safety-sensitive duties, such as operating 
heavy machinery or dealing with hazardous chemicals.  For example, 
according to the National Institute on Drug Abuse, employees who 
tested positive for marijuana had 55 percent more industrial accidents 
and 85 percent more injuries than those who tested negative for 
marijuana use.292  While the adoption of a drug-free workplace policy 
would be a feasible means of eliminating or materially reducing the 
hazard, state laws mandating coverage of medical marijuana interfere 
with employers’ ability to successfully implement such a policy.  
G. TORT LIABILITY  
Finally, an employer could be liable for the acts of an impaired 
employee if such employee injures a third party or causes damage to the 
third party’s property while acting within the scope of their 
employment.293  The third party could sue under common law tort 
 
 288 Letter from John B. Miles to Patrick J. Robinson, supra	note 285.. 
 289 29 U.S.C. § 666. 
	 290	 NSC	 to	 Employers:	 Allow	 NO	 Cannabis	 Use	 Among	Workers	 in	 Safety	 Sensitive	
Positions, INDUS. SAFETY & HYGIENE NEWS (Oct. 22, 2019), 
https://www.ishn.com/articles/111721-nsc-to-employers-allow-no-cannabis-use-
among-workers-in-safety-sensitive-positions.  
	 291	 Id. 
	 292	 Marijuana	 Research	 Report:	How	Does	Marijuana	Use	 Affect	 School,	Work,	 and	
Social	 Life?, NAT’L INST. ON DRUG ABUSE (July 2020), 
https://www.drugabuse.gov/publications/research-reports/marijuana/how-does-
marijuana-use-affect-school-work-social-life.  
	 293	 See,	e.g., Otis Eng’g Corp. v. Clark, 668 S.W.2d 307, 311 (Tex. 1984) (holding that 
an employer has a duty to exercise reasonable prudence to prevent an employee from 
“causing an unreasonable risk of harm to others” after the employer permitted a visibly 
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doctrine of vicarious liability, including respondeat superior.294  
Respondeat superior has been used to hold employers liable in 
situations in which employees injured or assaulted others as a result of 
intoxication or drug use.295  Under the theory of respondeat superior, 
employers are vicariously liable for the actions of their employees.296  To 
hold an employer liable under respondeat superior, plaintiffs usually 
must satisfy the scope-of-employment test.297  The scope-of-
employment test requires that an employee “be acting, at least in part, 
with the motivation to be about the employer’s business” and the 
employee’s action must be foreseeable.298  
For example, in Ira	 S.	 Bushey	 &	 Sons,	 Inc.	 v.	 United	 States,299 a 
drydock owner sued the United States after a member of the U.S. Coast 
Guard returned to his ship under the influence of alcohol and turned the 
drydock’s water flow control valves, causing the drydock’s tanks to 
flood.300  As a result, the ship listed, slid off its blocks, and fell against the 
wall, partially sinking the ship and the drydock.301  The defendant 
argued that it should not be held liable for the actions of its employee 
because the employee was not acting “within the scope of 
employment.”302  The Second Circuit Court of Appeals noted that 
vicarious liability is based on foreseeability.303  It stated that the Coast 
Guard member’s conduct “was not so ‘unforeseeable’ as to make it 
unfair to charge the government with responsibility . . . . The employer 
should be held to expect risks . . .  which arise ‘out of and in the course 
of’ his employment of labor.”304  The court noted that “it was foreseeable 
that crew members crossing the drydock may negligently or even 
intentionally damage it.”305  Additionally, the court noted that it was 
foreseeable that a seaman would “find solace for solitude by copious 
 
intoxicated employee to drive home, resulting in a fatal automobile accident).  Fitting, 
supra	note 272, at 271–72. 
 294 Laura L. Hirschfield, Legal	Drugs?	Not	Without	Legal	Reform:	The	Impact	of	Drug	
Legalization	on	Employers	Under	Current	Theories	of	Enterprise	Liability, 7 CORNELL J. L & 
PUB. POL’Y 757, 760 (1998). 
 295 Fitting, supra	note 272, at 271–72. 
 296 Fitting, supra	note 272, at 271–72. 
 297 Fitting, supra	note 272, at 271. 
 298 Fitting, supra	note 272, at 271-72. 
 299 Ira S. Bushey & Sons, Inc. v. United States, 398 F.2d 167 (2d Cir. 1968). 
	 300	 Id.	at 168.	
	 301	 Id. 
	 302	 Id.	at 170. 
	 303	 Id. at 172. 
 304 Bushey & Sons, Inc. v. United States, 398 F.2d 167, 171-72; Hirschfield, supra	note 
294, at 796.  
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resort to the bottle while ashore.”306  The court therefore ruled that the 
U.S. was vicariously liable for the Coast Guard member’s actions.307 
Likewise, under the proposed state laws, an employer may be 
required to cover non-FDA-approved cannabis products as part of 
workers’ compensation benefits, or an employee may have a health plan 
that covers such products.  It would be foreseeable that an employee 
under the influence of THC while acting within his or her scope of work, 
could cause injury or property damage, resulting in vicarious liability 
for the employer.  
H. OTHER DISINCENTIVES TO COVER MARIJUANA PRODUCTS 
Currently, many health plans only cover FDA-approved drugs with 
limited exceptions.308  Health plans generally do not cover non-FDA-
approved products because they have not undergone the FDA’s rigorous 
safety and efficacy process, and as such, there is no way to guarantee 
such products’ potency, dosage, or purity.  In addition, non-FDA-
approved products are not required to comply with good manufacturing 
practices.309  
Moreover, employers may be hesitant to cover non-FDA-approved 
products through workers’ compensation or health plans because doing 
so could be seen as condoning the use of such products at work.  Yet, if 
an employee is under the influence in the workplace, the employee 
could face negative repercussions and the employer could be subject to 
liability.  For example, the U.S. Department of Transportation (DOT) has 
a zero-tolerance policy for marijuana use and has announced that state 
initiatives have no bearing on the DOT’s regulated drug testing 
program.310  The policy states that the DOT “will not verify a drug test as 
negative based upon information that a physician recommended that 
the employee use ‘medical marijuana’ when states have passed ‘medical 
marijuana’ initiatives” because the DOT “want[s] to assure the traveling 
 
	 306	 Id.	at 171-72; Hirschfield, supra	note 294, at 796. 
	 307	 See	Bushey & Sons, 398 F.2d	at 172. 
	 308	 See,	 e.g., Commercial	 Claim	 Payment	 Bulletin	 –	 Pharmacy	 Benefit:	 Non‐FDA	
Approved	 Products (Jan. 1, 2021), INDEPENDENCE BLUE CROSS,	
https://www.ibx.com/documents/35221/56638/non-fda-approved-
medication.pdf/2b052ab2-2194-3502-f044-f3ecd5082a1f?t=1593556692733; Drugs	
Never	 Covered	 by	 Medicare, PRIORITY HEALTH,	
https://www.priorityhealth.com/medicare/drug-coverage/covered-drugs/never-
covered (last visited Feb. 28, 2021) (noting that nonprescription drugs and non-FDA-
approved products are excluded from coverage). 
	 309	 DOT	 “Recreational	 Marijuana”	 Notice, U.S. DEP’T TRANSP. (Feb. 1, 2017), 
https://www.transportation.gov/odapc/dot-recreational-marijuana-notice. 
	 310	 Id.; DOT	 “CBD”	 Notice, U.S. DOT (Feb. 18, 2020), 
https://www.transportation.gov/odapc/cbd-notice.  
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public that [the] transportation system is the safest it can possibly 
be.”311  Additionally, the DOT issued a policy on hemp-derived CBD 
products containing less than 0.3 percent of THC.312  The DOT notes that 
many CBD products purporting to comply with the Farm Bill may in fact 
contain more than 0.3 percent of THC, and therefore, may produce 
unexpected positive drug test results.313  As such, the agency has warned 
that “CBD use is not a legitimate medical explanation for a laboratory-
confirmed marijuana positive result” and “consumers should beware 
purchasing and using” such products.314  Thus, if state law required 
DOT-governed employers to cover marijuana through workers’ 
compensation or health plans and an employee uses marijuana 
products, the employee could face negative ramifications, including 
termination of employment.315   
 
IV. Recommendations	
To protect residents’ health and safety, states should not enact laws 
mandating that health plans and workers’ compensation cover 
marijuana.  Such laws cannot exist legally until Congress or the FDA 
removes marijuana from Schedule I and the FDA creates a new 
regulatory pathway for non-FDA-approved cannabis products used for 
the treatment of specific conditions.  While both Congress and the DEA 
have considered de-scheduling marijuana several times over the years, 
both have declined to do so.  
To the extent that ERISA preempts state law, employers should 
voluntarily choose not to cover non-FDA-approved cannabis products 
due to the risk of criminal and tort liability, and the various employee 
safety and efficacy concerns addressed above.  Instead, employers 
should only cover FDA-approved products so that their employees have 
access to safe and effective drugs.  If states pass laws requiring coverage 
of non-FDA-approved products, employers could deny coverage and 
challenge those laws in court by applying similar legal arguments as 
those presented in Bourgoin.  Additionally, it is important for employers 
to educate their employees on the risks of non-FDA-approved cannabis 
 
	 311	 DOT	“Recreational	Marijuana”	Notice, supra	note 309. 
	 312	 DOT	“CBD”	Notice, supra	note 310. 
	 313	 DOT	“CBD”	Notice, supra	note 310. 
	 314	 DOT	“CBD”	Notice, supra	note 310. 
 315 DOT employees likely to face discipline include: school bus drivers, truck drivers, 
train engineers, subway operators, aircraft maintenance personnel, transit fire-armed 
security personnel, ship captains, and pipeline emergency response personnel, among 
others.  DOT	“Recreational	Marijuana”	Notice, supra	note 309. 
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products so that they are less likely to seek coverage or reimbursement 
for such products.   
 
V. Conclusion	
Non-FDA-approved cannabis products pose health and safety risks 
to employees and liability risks for employers.  Moreover, state laws that 
would require employers to cover such products through health plans 
or workers’ compensation benefits conflict with, and are preempted by, 
federal laws such as the CSA.  As such, states should not enact such 
mandates. 
 
